

1 ***Kir2.1 mutations differentially increase the risk of flecainide proarrhythmia in***  
2 ***Andersen Tawil Syndrome***

3  
4 Francisco M. Cruz, PhD<sup>1,\*</sup>, Ana I. Moreno-Manuel, MSc<sup>1</sup>, Patricia Sánchez Pérez, PhD<sup>1</sup>,  
5 Juan Manuel Ruiz-Robles, MSc<sup>1</sup>, Paula García Socuellamos, PhD<sup>1</sup>, Lilian K. Gutiérrez,  
6 MSc<sup>1</sup>, María Linarejos Vera-Pedrosa, MSc<sup>1</sup>, Amaia Talavera Gutierrez, PhD<sup>1</sup>, Gema  
7 Mondéjar Parreño, PhD<sup>1</sup>, Álvaro Macías, PhD<sup>1</sup>, Isabel Martínez-Carrascoso, MSc<sup>1</sup>,  
8 Francisco J Bermúdez-Jiménez, MD, PhD<sup>1,4,5</sup>, Salvador Arias Santiago, MD, PhD,<sup>5</sup>  
9 Fernando Martínez de Benito, PhD<sup>1,2</sup>, Aitana Braza-Boils, PhD<sup>2,6</sup>, Carmen Valenzuela,  
10 PhD<sup>9</sup>, CA Morillo, MD<sup>1,10</sup>, Esther Zorio, MD, PhD<sup>2,6,7,8</sup>, Juan Jiménez-Jaimez, MD<sup>4,5</sup>, José  
11 Jalife, MD, PhD<sup>1,2,3,\*</sup>.

12  
13 <sup>1</sup>Spanish National Centre for Cardiovascular Research (CNIC), Madrid, Spain.

14 <sup>2</sup>Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV),  
15 Madrid, Spain.

16 <sup>3</sup>Departments of Medicine and Molecular and Integrative Physiology, University of  
17 Michigan, Ann Arbor, MI, USA.

18 <sup>4</sup>Cardiology Service, Virgen de las Nieves University Hospital, Granada, Spain.

19 <sup>5</sup>Institute of Biosanitary Research of Granada (IBS), Spain.

20 <sup>6</sup>CAFAMUSME Research Group, Instituto de Investigación Sanitaria La Fe, Valencia,  
21 Spain.

22 <sup>7</sup>Inherited Cardiac Disease Unit, University and Polytechnic Hospital La Fe, Valencia,  
23 Spain.

24 <sup>8</sup>Medicine Department, University of Valencia, Spain.

25 <sup>9</sup>Biomedical Research Institute Sols-Morreale (IIBM), Madrid, Spain.

26 <sup>10</sup>Department of Cardiac Sciences, Libin CVI, University of Calgary, Canada.

27  
28 **Short Title:** ATS1 mutations and flecainide proarrhythmia

29  
30 \*Corresponding authors:

31 José Jalife, MD, PhD.  
32 Cardiac Arrhythmia Laboratory  
33 Centro Nacional de Investigaciones Cardiovasculares (CNIC)  
34 Melchor Fernández Almagro 3, 28029 Madrid, Spain  
35 Email: [jjalife@cnic.es](mailto:jjalife@cnic.es)  
36 Telephone: +34-91 453 12 00 (Ext. 1512)  
37 FAX: +34-91 453 12 65

38  
39 Francisco Miguel Cruz, PhD.  
40 Cardiac Arrhythmia Laboratory  
41 Centro Nacional de Investigaciones Cardiovasculares (CNIC)  
42 Melchor Fernández Almagro 3, 28029 Madrid, Spain  
43 Email: [fmacruz@cnic.es](mailto:fmacruz@cnic.es)  
44 Telephone: +34-91 453 12 00  
45 FAX: +34-91 453 12 65

46  
47 **Keywords:** Ion channel diseases, Kir2.1-Na<sub>v</sub>1.5 channelosome, ATS1, class-Ic AADs,  
48 Flecainide, Arrhythmias, Sudden Cardiac Death

49  
50  
51  
52  
53 **Total word count:**

54 **Abstract**

55 **Background:**

56 Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-  
57 Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic  
58 in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia  
59 and whether they might increase the risk of death in ATS1 patients with structurally  
60 normal hearts.

61

62 **Methods and Results:** Of 53 ATS1 patients reviewed from the literature, 54% responded  
63 partially to flecainide, with ventricular arrhythmia (VA) reduction in only 23%. Of the latter  
64 patients, VA persisted in 20-50%. Flecainide was ineffective in 23%, and surprisingly,  
65 13.5% suffered a non-fatal cardiac arrest. In five cardiac-specific ATS1 mouse models  
66 (Kir2.1<sup>Δ314-315</sup>, Kir2.1<sup>C122Y</sup>, Kir2.1<sup>G215D</sup> and Kir2.1<sup>R67W</sup> and Kir2.1<sup>S136F</sup>), flecainide or  
67 propafenone (40 mg/Kg i.p.) differentially prolonged the P wave, and the PR, QRS and  
68 QTc intervals compared to Kir2.1<sup>WT</sup>; Kir2.1<sup>S136F</sup> had milder effects. Flecainide increased  
69 VA inducibility in all mutant mice except Kir2.1<sup>S136F</sup>, which exhibited significant VA  
70 reduction. At baseline, Kir2.1<sup>G215D</sup> cardiomyocytes had the lowest inward rectifier K<sup>+</sup>  
71 channel (I<sub>K1</sub>) reduction, followed by Kir2.1<sup>C122Y</sup>, Kir2.1<sup>R67W</sup> and Kir2.1<sup>S136F</sup>. Kir2.1<sup>C122Y</sup>  
72 cardiomyocytes had a significant decrease in sodium inward current (I<sub>Na</sub>). Flecainide (10  
73 μM) slightly increased I<sub>K1</sub> density in Kir2.1<sup>WT</sup> and Kir2.1<sup>S136F</sup>, while it decreased both I<sub>K1</sub>  
74 and I<sub>Na</sub> in Kir2.1<sup>C122Y</sup> and Kir2.1<sup>R67W</sup>, despite normal trafficking of mutant channels. Optical  
75 mapping in ATS1 patient-specific iPSC-CM monolayers expressing Kir2.1<sup>C122Y</sup>, Kir2.1<sup>G215D</sup>  
76 and Kir2.1<sup>R67W</sup> showed an increase in rotor incidence at baseline and under flecainide,  
77 confirming the drug's proarrhythmic effect. Lastly, in-silico molecular docking predicts that  
78 the Kir2.1-Cys<sub>311</sub> pharmacophore-binding site is altered in Kir2.1<sup>C122Y</sup> heterotetramers,  
79 reducing flecainide accessibility and leading to channel closure and arrhythmias.

80

81 **Conclusions:** Class-Ic AADs are only partially effective and might be proarrhythmic in  
82 some ATS1 patients. Kir2.1 mutations impacting the resting membrane potential and  
83 cellular excitability create a substrate for life-threatening arrhythmias, raising significant  
84 concern about using these drugs in some ATS1 patients.

85 **CLINICAL PERSPECTIVE**  
86 **NOVELTY AND SIGNIFICANCE**

87

88 **What is known?**

- 89
- 90 • Andersen-Tawil syndrome type 1 (ATS1) is a rare autosomal dominant disease  
91 caused by loss-of-function mutations in the *KCNJ2* gene, which encodes the Kir2.1  
92 channel responsible for the repolarizing, strong inwardly rectifying current  $I_{K1}$ .
  - 93 • ATS1 treatment is empirical and subject to clinical judgment. It includes the use of  
94 class-Ic antiarrhythmic drugs (AADs), mainly flecainide, alone or in combination  
95 with  $\beta$ -adrenergic blocking drugs. However, pharmacological treatment is partial  
96 and might fail, leading to life-threatening ventricular arrhythmias (VA) and sudden  
97 cardiac death (SCD) in some ATS1 patients.
  - 98 • Some ATS1 mutations are known to disrupt the Kir2.1-Nav1.5 channelosome in  
99 mice and human iPSC-CMs, with consequent reductions in cardiac excitability and  
conduction velocity (CV), leading to VA, which may be exacerbated by flecainide.

100 **What new information does this article contribute?**

- 101
- 102 • In our analysis of 53 ATS1 patients, flecainide showed partial effectiveness. While  
103 a few patients experienced complete disappearance of VA, others had persistent  
104 arrhythmias and even suffered non-fatal cardiac arrest while on medication.
  - 105 • In murine models expressing five relevant ATS1 mutations, flecainide or  
106 propafenone produced differential alteration in the P wave, PR, QRS and QTc  
107 intervals, and increased VA inducibility compared with Kir2.1<sup>WT</sup> mice. Additionally,  
108 flecainide differentially affected  $I_{K1}$  and the Na<sup>+</sup> inward current ( $I_{Na}$ ) current  
109 densities despite normal trafficking of mutant channels.
  - 110 • In patient-specific induced pluripotent stem cell derived cardiomyocyte (iPSC-CM)  
111 monolayers flecainide reduced CV and increased rotor incidence, confirming the  
112 drugs' proarrhythmic effect.
  - 113 • *In-silico* molecular docking studies predicted that the Cys<sub>311</sub> pharmacophore  
114 binding site and flecainide accessibility are altered in mutated Kir2.1 channels,  
115 leading to premature channel closure and arrhythmias.
  - 116 • We conclude that class-Ic AADs are only partially effective and might be  
117 proarrhythmic in some ATS1 patients.
  - 118 • These findings raise concern about the use of class-Ic AADs in ATS1 patients and  
highlight the need for further studies to guide personalized therapy.

|     |   |  |
|-----|---|--|
| 119 | <b>Non-standard Abbreviation and Acronyms</b> |  |
| 120 | AAD   | Antiarrhythmic drug                                  |
| 121 | AP  | Action potential                                     |
| 122 | APD   | Action potential duration                            |
| 123 | ATS1  | Andersen-Tawil Syndrome Type 1                       |
| 124 | BiVT  | Bidirectional ventricular tachycardia                |
| 125 | CV  | Conduction velocity                                  |
| 126 | ECG   | Electrocardiogram                                    |
| 127 | hiPSC-CMs                                     | Induced pluripotent stem cell-derived cardiomyocytes |
| 128 | IC  | Isogenic control                                     |
| 129 | ICD   | Implantable cardiac defibrillator                    |
| 130 | i.p.  | Intraperitoneal                                      |
| 131 | i.v.  | Intravenously  |
| 132 | NSVT  | Nonsustained ventricular tachycardia                 |
| 133 | PIP <sub>2</sub>                              | Phosphatidylinositol-4, 5-bisphosphate               |
| 134 | PVC   | Premature ventricular contraction                    |
| 135 | PVT   | Polymorphic ventricular tachycardia                  |
| 136 | RMP   | Resting membrane potential                           |
| 137 | SASA  | Solvent Accessible                                   |
| 138 | SCD   | Sudden cardiac death                                 |
| 139 | SNRT  | Sinus node recovery time                             |
| 140 | TdP   | Torsades de pointe                                   |
| 141 | VA  | Ventricular arrhythmias                              |
| 142 | VE  | Ventricular extrasystoles                            |
| 143 | VT  | Ventricular tachycardia                              |
| 144 | WT  | Wild type  |

## 145 Introduction

146 Andersen-Tawil syndrome type 1 (ATS1) is a rare autosomal dominant disease  
147 caused by loss-of-function mutations in the *KCNJ2* gene, which codes the strong inward  
148 rectifier potassium channel Kir2.1 responsible for the repolarizing current  $I_{K1}$ .<sup>1</sup>  $I_{K1}$  plays a  
149 vital role maintaining the resting membrane potential (RMP) and the final phase of action  
150 potential (AP) repolarization. Thus, loss-of-function mutations in *KCNJ2* substantially  
151 decrease  $I_{K1}$ , with consequent prolongation of the AP duration (APD) and corrected QT  
152 (QTc) interval.<sup>2</sup> These events predispose ATS1 patients to a triad of symptoms including  
153 periodic paralysis, dysmorphias, and cardiac electrical alterations that may lead to high-  
154 burden polymorphic ventricular extrasystoles, biventricular tachycardia (BiVT), and  
155 sudden cardiac death (SCD)<sup>3</sup> by mutation-dependent mechanisms that are far from being  
156 fully understood. Accordingly, it is unknown why life-threatening arrhythmias occur in  
157 these patients, why some mutations have a more severe phenotype than others, even  
158 within the same family, and how to treat each individual patient. Currently ATS1 treatment  
159 is empirical and subject to clinical judgment.<sup>4</sup> Medical devices like implantable cardiac  
160 defibrillators (ICDs) are frequently indispensable in the management of severe and  
161 symptomatic cardiac arrhythmias. However, ICDs may induce inappropriate shocks and  
162 patients are not exempt from SCD risk.<sup>4-6</sup> Pharmacological treatment includes class-Ic  
163 antiarrhythmic drugs (AADs), mainly flecainide or propafenone alone or in combination  
164 with  $\beta$ -adrenergic blocking drugs.<sup>7,8</sup> However, class-Ic drugs may fail or are proarrhythmic  
165 in ATS1 patients<sup>4</sup> due to poorly understood mechanisms.

166 More than 90 ATS1-associated loss-of-function mutations have been identified and  
167 distributed throughout the Kir2.1 protein structure. Mutations may affect channel  
168 trafficking, channel gating, or ion selectivity properties through molecular mechanisms that  
169 are incompletely understood.<sup>9</sup> Additionally, Kir2.1 forms channelosomes with  $Na_v1.5$   
170 proteins, responsible for the sodium inward current ( $I_{Na}$ ).<sup>10-12</sup> This specialized molecular  
171 complex plays a crucial role in maintaining cardiac excitability and rhythm by stabilizing  
172 the RMP and initiating the AP, ensuring coordinated cardiac activity. We have previously  
173 shown that, in addition to sequestering the Kir2.1 protein in the Golgi apparatus,<sup>13</sup> the  
174 Kir2.1 <sup>$\Delta$ 314-315</sup> mutation also prevents  $Na_v1.5$  membrane trafficking, thus altering the  
175 function of both proteins *in-vitro* and *in-vivo*.<sup>20</sup> More recently, we demonstrated that, while  
176 maintaining trafficking ability, the extracellular Kir2.1<sup>C122Y</sup> mutation that disrupts  
177 interactions of the channel with phosphatidyl inositol 4,5-bisphosphate (PIP<sub>2</sub>) also  
178 produces temporal instability of both Kir2.1 and  $Na_v1.5$  proteins and reduces excitability  
179 *in-vivo*.<sup>14</sup> Thus, the above results underscore the complexity of the mechanisms governing  
180 Kir2.1- $Na_v1.5$  channelosome function, and it is clear that each ATS1 mutation exhibits  
181 distinct molecular mechanisms despite targeting the same gene. To date, only a handful  
182 of studies have addressed the potential alterations in the surrounding molecular context  
183 that governs cardiac activity, including  $Na_v1.5$  channels. There is, therefore, a significant  
184 discrepancy between what is known and what should be known regarding molecular  
185 mechanisms for a more effective treatment of each specific mutation leading to ATS1<sup>15,16</sup>.  
186 The lack of mechanistic knowledge significantly hinders our understanding of the cardiac  
187 arrhythmia phenotype and prevents progress in disease treatment and SCD prevention.  
188 No studies have been conducted to date to determine the impact of flecainide or any other  
189 class-Ic AADs on the electrical activity of the Kir2.1- $Na_v1.5$  channelosome, which could  
190 vary significantly depending on the specific ATS1 mutation.

191 In this article, we review available clinical data and demonstrate that the cardiac  
192 electrical response of ATS1 patients to class-Ic AADs is highly variable, and at times  
193 contrary to anticipated. While some patients benefit from the use of these drugs, others do  
194 not, and yet others may get worse. We hypothesize that the ultimate effect of class-Ic  
195 AADs in a given ATS1 patient will depend on the precise electrophysiological  
196 consequences of the Kir2.1 loss-of-function mutation. Specifically, we surmise that  
197 mutations impacting both RMP ( $I_{K1}$  reduction) and cellular excitability by altering  $Na_v1.5$   
198 function ( $I_{Na}$  reduction) and channel availability (through RMP-mediated depolarization),

199 may potentially create a substrate for life-threatening arrhythmias, particularly promoted  
200 by class-Ic AADs treatment. Our approach is multidisciplinary, and our results emphasize  
201 the need to elucidate the pathophysiology of arrhythmias in individual patients with ATS1,  
202 and identify an effective, more personalized therapy that reduces proarrhythmia risk.

## 203 **Materials & Methods**

204 **The authors declare that all supporting data are available within the article. Please**  
205 **see the Major Resources Table and Supplemental Methods for more details.**

206

207 **Ethics Statement.** All animal experimental procedures conformed to EU Directive  
208 2010/63EU and Recommendation 2007/526/EC. We obtained skin biopsies from patients  
209 carrying the Kir2.1<sup>C122Y</sup>, Kir2.1<sup>G215D</sup> and Kir2.1<sup>R67W</sup> mutation after written informed consent,  
210 previously approved by local institutional review (2020-411-1, 2020-582-1), according to  
211 the Ethics Committee for Research of CNIC and the Carlos III Institute (CEI PI58\_2019-  
212 v3), Madrid, Spain. The local ethics committees and the Animal Protection Area of the  
213 Comunidad Autónoma de Madrid (PROEX 111.4/20 and 226.5/23) approved the animal  
214 protocols.

215

216 **Mice.** We obtained 4-5-weeks-old C57BL/6J male mice from the Charles River  
217 Laboratories. Animals were reared and housed according to CNIC animal facility  
218 guidelines and regulations.

219

220 **AAV vector production, purification, and mouse model generation.** AAV vectors were  
221 generated using the cardiomyocyte-specific troponinT proximal promoter (cTnT) and  
222 encoding wildtype Kir2.1 (Kir2.1<sup>WT</sup>) or the ATS1 mutant channels (Kir2.1<sup>Δ314-315</sup>,  
223 Kir2.1<sup>C122Y</sup>, Kir2.1<sup>G215D</sup> and Kir2.1<sup>R67W</sup> and Kir2.1<sup>S136F</sup>), followed by tdTomato report.  
224 Vectors were packaged into AAV serotype 9 (AVV9) and produced by the triple  
225 transfection method, using HEK293T cells as described previously.<sup>17,18</sup> Mice were  
226 anesthetized with ketamine (60 mg/kg) and xylazine (20 mg/kg) by intraperitoneal (i.p.)  
227 route. Thereafter, mice were inoculated with  $3.5 \times 10^{10}$  viral particles through the femoral  
228 vein at a final volume of 50  $\mu$ L. Only well-inoculated animals were included in the studies.  
229 All experiments were performed 8-to-10 weeks after infection. *Ex-vivo* fluorescent signal  
230 confirming cardiac expression and distribution of protein expression was assessed as  
231 described.<sup>19</sup>

232

233 **Drugs.** Flecainide-acetate (10mg/ml injection solution; Mylan pharmaceuticals) and  
234 propafenone-hydrochloride (Sigma) were dissolved and administered i.p. in mice at a  
235 single dose of 40 mg/kg.<sup>20</sup> Fresh drug solutions were prepared for each experiment and  
236 further dilutions were carried out in external solution to obtain the desired final  
237 concentration for patch clamping and optical mapping experiments. Control solutions  
238 always contained the same solvent concentrations as the test solution. ECGs were  
239 recorded for 1 min at baseline and an additional 5 min after intraperitoneal injection of  
240 flecainide or propafenone. hiPSCs-CM monolayers were incubated in the presence of 1  
241  $\mu$ M flecainide and isolated mouse cardiomyocytes expressing Kir2.1<sup>WT</sup>, Kir2.1<sup>C122Y</sup>,  
242 Kir2.1<sup>R67W</sup>, Kir2.1<sup>G215D</sup>, Kir2.1<sup>R67W</sup> and Kir2.1<sup>S136F</sup> channels were recorded at baseline and  
243 after 10 min of incubation with a final concentration of 10  $\mu$ M of flecainide (IC<sub>50</sub> for Na<sub>v</sub>1.5  
244 channels).<sup>21</sup>

245

246 **Surface ECG recording.** Mice were anesthetized using isoflurane inhalation (0.8-1.0%  
247 volume in oxygen) and maintained at 37°C on a heating plate. Four-lead surface ECGs  
248 were recorded for 6 min (1 min baseline + 5 min after i.p. drug) using subcutaneous limb  
249 electrodes connected to an MP36R amplifier unit (BIOPAC Systems). Data acquisition  
250 and analyses were performed using AcqKnowledge software.

251

252 **In-vivo intracardiac recording, stimulation, and drug administration.** An octopolar  
253 catheter (Science) was inserted through the jugular vein and advanced into the right  
254 ventricle as previously described.<sup>22</sup> VA inducibility was assessed by applying consecutive  
255 trains at 10Hz and 25Hz, respectively.

256

257 **Cardiomyocyte isolation.** The procedure was performed as previously described.<sup>23</sup> (See  
258 *Supplemental Methods*).

259  
260 **Patch-clamping in isolated cardiomyocytes.** The whole-cell patch-clamp technique as  
261 well as data analysis procedures and internal and external solutions (***Supplementary***  
262 ***Table 1***) were similar to those previously described.<sup>9–13</sup> Details are presented in the  
263 *Supplemental Methods*.

264  
265 **Generation, culture, and differentiation of iPSC-CMs.** We reprogrammed primary  
266 fibroblasts derived from skin biopsies from ATS1 patients (C122Y, R67W and G215D) to  
267 iPSCs using the Sendai virus for transfection of Yamanaka's factors: OCT4, KLF4, c-Myc,  
268 and SOX2, as previously described.<sup>24</sup> HiPSCs were differentiated into hiPSC-CMs using  
269 small molecules-mediated canonical Wnt pathway modulation as previously described.<sup>25,26</sup>  
270 HiPSC-CMs were purified from non-myocytes following the MACS negative selection  
271 protocol (Miltenyi Biotec Kit) and seeded for 7 days on a PDMS substrate to improve  
272 cardiomyocyte maturation. See *Supplemental Methods* for details.

273  
274 **Optical Mapping in iPSC-CMs monolayers.** Phase, conduction velocity and activation  
275 maps were generated at baseline and after pacing (from 1000-to-400 ms). Flecainide (5  
276  $\mu\text{M}$ ) was incubated for 1 min before pacing, and experiments were carried out as  
277 previously described.<sup>27,28</sup>

278  
279 **Statistical analyses.** To determine the statistical power and minimum sample size in our  
280 experiments, we did a power calculation using R base “power.t.test” or “power.anova.test”  
281 function depending on data analysis. We used a significance level (alpha=0.05), power (1-  
282 beta=80%), the estimated difference between control and experimental data for t-test, and  
283 estimated variances for ANOVA. We used GraphPad Prism software versions 7.0 and 8.0.  
284 For non-Gaussian distributions, we applied the non-parametric Mann-Whitney test. We  
285 used one- or two-way ANOVA corrected by Šidák's multiple comparisons test. We used  
286 Grubb's test for analysis of outliers. Data are expressed as mean  $\pm$  SEM, and differences  
287 are considered significant at  $p < 0.05$  (\* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ ). Note  
288 that “N” refers to the number of mice or hiPSC-CMs differentiations used and “n” to the  
289 number of cells analyzed per mouse or monolayer.



290 **Results**

291

292 **Ventricular arrhythmias persist in ATS1 patients despite flecainide therapy.**

293 We systematically scanned the existing ATS1 literature assessing the effects of an  
294 empirical, “one-size-fits-all” antiarrhythmic treatment, specially the use of class-Ic AADs  
295 flecainide or propafenone, either alone or in combination with  $\beta$ -blockers. Our analysis  
296 included both genders, all age ranges and diverse origins, while specifically excluding  
297 those with structural or ischemic heart disease. The search yielded a limited number of  
298 publications (23), most of which were isolated case reports (~87%) or small series (less  
299 than 12 patients; ~13%), without any follow-up report. We evaluated the cardiac  
300 phenotype, therapy and clinical response in a total of 53 documented patients each  
301 carrying one of more than 20 different Kir2.1 loss-of-function mutations (**Table 1**). We  
302 incorporate a recently published study<sup>14</sup> including a Kir2.1<sup>C122Y</sup> proband, who presented  
303 several syncopal polymorphic VT and suffered three proper ICD shocks between ages 25-  
304 35 under sodium channel blocker administration. A Holter trace (**Figure 1A**) shows an  
305 electrogram with long-short coupling initiating polymorphic VT (PVT) suggesting either  
306 ineffective therapy or a drug’s proarrhythmic effect.

307 We also reproduce previously unreported tracings from two members, mother and  
308 daughter, of a Spanish family of Caucasian origin with a final diagnosis of ATS1. Both  
309 patients came to the consult of one of the authors (EZ) more than a decade after being  
310 studied in other centers and treated ineffectively with multiple drug combinations. Both  
311 carried a heterozygous missense *KCNJ2* variant (c.644 G>A, Gly215Asp (G215D))  
312 previously reported to disrupt Kir2.1-PIP<sub>2</sub> interactions.<sup>29</sup> The mother, patient I-1, was a  
313 female who experienced worsening dyspnea and fatigue in their 60’s (**Case 1 in Table 1**).  
314 The ECG showed high burden ventricular extrasystoles (VE) and bidirectional VT (**Figure**  
315 **1B, upper panel**). The patient initially refused  $\beta$ -blocker treatment and was started on  
316 flecainide (100 mg per day), but there was no improvement. Flecainide was subsequently  
317 combined with small dose nadolol (20mg mg/day). While there was some improvement  
318 the patient continued having high burden ventricular extrasystoles (from 3.2 to 18%) and  
319 bidirectional VT (**Figure 1B, middle panel**). Flecainide was then switched to propafenone  
320 (225 mg/kg/day), which led to another hospital admission due to non-syncopal dizziness  
321 and continued high VA burden (11.2% with NSVT) (**Figure 1B, bottom panel**). The patient  
322 experienced intolerance to mexiletine (7.7 mg per day), and after rejecting ICD  
323 implantation, she is under nadolol alone, but continues with multiple ventricular  
324 extrasystoles (up to 32%) and NSVT (**Figure 1B**) including self-limiting AF (<5 min).

325 The daughter, patient II-1, was initially referred to the hospital in their 20’s for  
326 syncope and multiple VEs (**Case 1-daughter in Table 1**). Nadolol (20mg) combined with  
327 flecainide (100 mg/day) partially reduced in VE burden that finally led to a syncope and an  
328 ICD was implanted. Treatment was maintained and resulted in a self-limiting VT episode.  
329 Medication was changed to nadolol (20mg) and propafenone (375mg per day). She has  
330 not reported syncope since then and the NSVT burden has declined from 35% under  
331 flecainide to 10% with propafenone. Actually, she remains clinically more stable, but the  
332 arrhythmias have not completely disappeared.

333 We also present the case of an ATS1 male proband in their 40’s carrying the PIP<sub>2</sub>-  
334 associated Kir2.1<sup>R67W</sup> mutation (**Case 2 in Table 1**).<sup>30</sup> The patient exhibited characteristic  
335 dysmorphic features including clinodactyly and micrognathia, and had experienced  
336 periodic muscle paralysis since the age of 8, particularly during intense physical activity.  
337 Initial treatment consisted of nadolol (120 mg/day) and acetazolamide (250 mg/day).  
338 Holter monitoring revealed a QT interval of 480 ms (QTc 434 ms), prominent U waves,  
339 high density polymorphic VE and 7 episodes of nonsustained BiVT. The 3-lead ECG time  
340 series in **Figure 1C** shows frequent premature ventricular complexes and the Holter  
341 fragment at the bottom shows an episode of polymorphic VT. Nadolol was then switched  
342 to flecainide (100 mg/12h). However, while NSVT runs were no longer observed in  
343 subsequent 24h-Holter monitoring, the patient continued with high density polymorphic VE  
344 (>20%) and palpitations. Additionally, flecainide induced an asymptomatic 8-sec cardiac

345 pause and extreme sinus bradycardia, with an average heart rate of 50 bpm and a  
346 minimum of 28 bpm. Currently, the patient is on nadolol (80mg/day) and has been  
347 scheduled for left cardiac sympathetic denervation.

348 The Venn diagram presented in **Figure 2** includes the 53 documented patients  
349 reported in the 23 publications listed on **Table 1**. Only 23% of patients were successfully  
350 treated with complete or greater than 90% VA suppression; 54% presented moderate  
351 improvement during class-Ic AADs treatment, maintaining 20-50% of VA. More  
352 importantly, in 23% of the cases, flecainide or propafenone were completely ineffective in  
353 treating arrhythmias. Surprisingly, a total of 7 patients (13.5%) experienced an additional  
354 non-fatal cardiac arrest in the presence of medication. Altogether, the results strongly  
355 suggest that the use of flecainide and other class-Ic AADs is debatable in a significant  
356 proportion of ATS1 patients due to great variability in outcomes and the potential for life-  
357 threatening proarrhythmia. Therefore, the intolerance to class-Ic AADs experienced by  
358 many of these patients may depend on the specific ATS1-causative mutation, highlighting  
359 the urgent need for molecular studies to investigate the underlying pathophysiological  
360 mechanisms.

361

### 362 **Class-Ic AADs alter cardiac conduction in ATS1 mouse models**

363 The foregoing data demonstrate that the response of ATS1 patients to  
364 conventional AADs therapy is highly variable and may depend on the specific mutation  
365 and other intermediate factors that affect the patient's electrical phenotype. To gain  
366 insight into what such factors may be, we have generated five relevant cardiac-specific  
367 ATS1 mouse models using well-established AAV technology.<sup>19</sup> In addition to wildtype  
368 (Kir2.1<sup>WT</sup>) mice, we generated mice with the cardiac-specific trafficking deficient Kir2.1<sup>Δ314-  
369 315</sup> mutation and the mutation Kir2.1<sup>C122Y</sup> that disrupts Kir2.1-PIP<sub>2</sub> interaction, both  
370 affecting Kir2.1-Na<sub>v</sub>1.5 channelosomes and excitability.<sup>14,23</sup> We also included mice with  
371 the PIP<sub>2</sub>-related Kir2.1<sup>G215D</sup> and Kir2.1<sup>R67W</sup> mutations found in our ATS1 patients. Further,  
372 we incorporated the unrelated Kir2.1<sup>S136F</sup>, which has been shown to alter the K<sup>+</sup> selectivity  
373 filter by modifying the highly conserved GYG motif.<sup>9,31,32</sup> Surface ECG recordings obtained  
374 8 weeks after AAV9-mediated inoculation showed that, compared with Kir2.1<sup>WT</sup>, a single  
375 dose of flecainide (40 mg/kg; i.p.)<sup>20</sup> progressively prolonged the P wave, PR interval, and  
376 QRS complex duration in all mutant mice over ~6 min. However, the effects were different  
377 depending on the mutation, with Kir2.1<sup>R67W</sup> > Kir2.1<sup>G215D</sup> > Kir2.1<sup>Δ314-315</sup> > Kir2.1<sup>C122Y</sup> >  
378 Kir2.1<sup>S136F</sup> (**Figure 3A and Supplemental Figure 1**). These data suggest that the varying  
379 effects of each mutation reducing Kir2.1 and Na<sub>v</sub>1.5 membrane function, together with  
380 drug-induced I<sub>Na</sub> blockade synergized to prolong mutation-dependent intra-atrial (P-wave)  
381 atrioventricular (PR interval) and intraventricular (QRS) conduction. Additionally, all  
382 mutations prolonged the QTc interval to varying degrees, suggesting a differential  
383 flecainide-mediated I<sub>K1</sub> response among mutant channels (Kir2.1<sup>C122Y</sup> > Kir2.1<sup>G215D</sup> >  
384 Kir2.1<sup>Δ314-315</sup> > Kir2.1<sup>R67W</sup> > Kir2.1<sup>S136F</sup>). Propafenone (40 mg/Kg; i.p.) also prolonged all  
385 ECG parameters compared with WT but to a lesser extent than flecainide, with the  
386 following pattern: Kir2.1<sup>Δ314-315</sup> > Kir2.1<sup>C122Y</sup> > Kir2.1<sup>G215D</sup> > Kir2.1<sup>R67W</sup> > Kir2.1<sup>S136F</sup> (**Figure  
387 3B**).

388 Analysis of the ECGs revealed that in addition to altering the duration of intervals,  
389 many of the Kir2.1<sup>Δ314-315</sup>, Kir2.1<sup>C122Y</sup>, Kir2.1<sup>G215D</sup> and Kir2.1<sup>R67W</sup> mice developed  
390 spontaneous VA, some of them complex, when administered flecainide (**Figure 4**). **Figure  
391 4A** shows data from a Kir2.1<sup>C122Y</sup> mouse with frequent closely coupled PVCs with  
392 compensatory pauses. In **Figure 4B**, data from a Kir2.1<sup>G215D</sup> animals show several runs of  
393 monomorphic NSVT. **Figure 4C** is a recording of a 9:1 sinoatrial block pattern in a  
394 Kir2.1<sup>Δ314-315</sup> mouse. Finally, **Figure 4D** shows an example with frequent episodes of  
395 NSVT of variable duration in a Kir2.1<sup>R67W</sup> mouse.

396

### 397 **Flecainide fails to prevent arrhythmia inducibility in most ATS1 mutant mice**

398 Our data compilation indicates that the cardiac electrical response of ATS1  
399 patients to class-Ic AADs is highly variable. Propafenone has demonstrated limited

400 success in managing VA compared to flecainide, and patients often require alternative  
401 treatment options. Therefore, hereafter we focus solely on flecainide effects on  
402 experimental animals and human cells. To test whether flecainide modifies arrhythmia  
403 susceptibility in ATS1 mouse models we conducted *in-vivo* catheter-based, intracardiac  
404 electrical stimulation experiments in all groups of animals (**Figure 5**). At baseline, all  
405 mutant animals (Kir2.1<sup>Δ314-315</sup>, 80%; Kir2.1<sup>C122Y</sup>, 50%; Kir2.1<sup>G215D</sup>, 50%, Kir2.1<sup>R67W</sup>, 66,67%;  
406 Kir2.1<sup>S136F</sup>, 62.5%) were inducible for VA developing NSVT episodes of variable duration.  
407 In contrast, only 1 out of 10 (10%) Kir2.1<sup>WT</sup> mice was inducible (**Figure 5A and B, top**).

408 Flecainide administration was beneficial in Kir2.1<sup>S136F</sup> mice, reducing VT inducibility  
409 to 1 out of 8 animals (12.5%). However, a substantial increase in NSVT inducibility was  
410 demonstrated in the rest of mutant mice after a single dose of flecainide (40 mg/Kg; i.p.)  
411 (**Figure 5B bottom**). In the presence of the drug, 70% of Kir2.1<sup>Δ314-315</sup>, 62.5% of  
412 Kir2.1<sup>C122Y</sup>, 83,34% of Kir2.1<sup>G215D</sup>; 100% of Kir2.1<sup>R67W</sup>; but only 10% of Kir2.1<sup>WT</sup> mice were  
413 NSVT inducible. Importantly, although at baseline the mean duration of NSTV did not  
414 exceed 1 sec in any of the mutant mice, a single dose of 40 mg/Kg flecainide increased  
415 the duration of the induced VA to more than one second in all, except Kir2.1<sup>G215D</sup> and  
416 Kir2.1<sup>S136F</sup> mutant mice (**Figure 5C and D**). Such a variable response to flecainide  
417 resembles the heterogeneous clinical outcomes observed in ATS1 patients (**Table 1**).

418 We did observe significant alterations in sinus node function upon ventricular  
419 intracardiac stimulation in all mutant mice. We measured sinus node recovery time  
420 (SNRT) as the interval between the last pacing stimulus and the first atrial complex of  
421 sinus origin in recordings whose response to intracardiac stimulation was not  
422 arrhythmogenic (**Supplemental Figure 2**). At baseline, SNRT was longer in Kir2.1<sup>Δ314-315</sup>,  
423 Kir2.1<sup>C122Y</sup> and Kir2.1<sup>R67W</sup> mice than Kir2.1<sup>WT</sup> (**Supplemental Figure 2A**; SNRT, 280 ± 98  
424 ms in Kir2.1<sup>Δ314-315</sup>; 327 ± 65 ms in Kir2.1<sup>C122Y</sup>; 213 ± 69 ms in Kir2.1<sup>G215D</sup>; 291 ± 83 ms in  
425 Kir2.1<sup>R67W</sup>; and 196 ± 49 ms in Kir2.1<sup>S136F</sup>; vs 218 ± 48 ms in Kir2.1<sup>WT</sup> mice). Notably,  
426 flecainide led to a significant SNRT increase in Kir2.1<sup>Δ314-315</sup>, Kir2.1<sup>C122Y</sup> and Kir2.1<sup>R67W</sup>  
427 mice, suggesting impaired sino-atrial excitability and conduction. In contrast, SNRT in  
428 Kir2.1<sup>WT</sup>, Kir2.1<sup>G215D</sup> and Kir2.1<sup>S136F</sup> mice showed no significant change compared to pre-  
429 treatment values (**Supplemental Figure 2B**; Kir2.1<sup>Δ314-315</sup>, 340 ± 116 ms; Kir2.1<sup>C122Y</sup>, 462  
430 ± 182 ms; Kir2.1<sup>G215D</sup>, 240 ± 83 ms; Kir2.1<sup>R67W</sup>, 502 ± 192 ms; and Kir2.1<sup>S136F</sup>, 218 ± 76 ms  
431 ; vs Kir2.1<sup>WT</sup>, 224 ± 51 ms). While demonstrating therapeutic promise in Kir2.1<sup>S136F</sup>  
432 animals, the results suggest that flecainide potentially harms sinus node function in  
433 Kir2.1<sup>Δ314-315</sup>, Kir2.1<sup>C122Y</sup> and Kir2.1<sup>R67W</sup> mice. In addition, the ECG also revealed  
434 prolonged P wave duration (**Figure 3**), suggesting delayed conduction through  
435 Bachmann's bundle and the interatrial pathways, which is commonly associated with  
436 AF.<sup>33</sup> Altogether, these results demonstrate a high variability in response to flecainide and  
437 suggest that susceptibility to proarrhythmia is dependent on the specific mutation. Thus,  
438 understanding the intricacies of flecainide's actions in diverse genetic contexts is crucial  
439 for refining arrhythmia management strategies and improving ATS1 patient care.

440

#### 441 **Flecainide impairs Kir2.1-Na<sub>v</sub>1.5 channelosome function in mutant cardiomyocytes**

442 Flecainide and propafenone have been shown to increase I<sub>K1</sub> by interfering with  
443 polyamine blockade in heterologous HEK293 cells expressing Kir2.1<sup>WT</sup> channels,<sup>34,35</sup> but  
444 this effect has not been demonstrated in adult cardiomyocytes. To gain insight into the  
445 ionic mechanisms of the proarrhythmic effects of flecainide in some of the ATS1 mice, we  
446 used equimolar therapeutic concentrations<sup>21</sup> of the drug in patch-clamp experiments  
447 focusing on I<sub>K1</sub> and I<sub>Na</sub> (**Figure 6**). We abstained from analyzing isolated Kir2.1<sup>Δ314-315</sup>  
448 cardiomyocytes due to the severe impact on I<sub>K1</sub>, which was completely absent.<sup>20</sup>  
449 Superfusion of flecainide (10 μM) slightly increased I<sub>K1</sub> in Kir2.1<sup>WT</sup> and Kir2.1<sup>S136F</sup>  
450 cardiomyocytes (**Figure 6A**). However, contrary to expected, this drug significantly  
451 reduced I<sub>K1</sub> in Kir2.1<sup>C122Y</sup> and Kir2.1<sup>R67W</sup> cardiomyocytes. Flecainide did not modify I<sub>K1</sub> in  
452 Kir2.1<sup>G215D</sup> cardiomyocytes, as shown by the I/V plots and the I<sub>K1</sub> slope values measured  
453 between -140 and -50 mV (**Figure 6A and C**). Notably, in Kir2.1<sup>G215D</sup> cardiomyocytes,  
454 flecainide produced a small increase in the outward current, an effect that was nonexistent

455 at baseline, although it did not exceed the levels observed in mutant Kir2.1<sup>C122Y</sup> and  
456 Kir2.1<sup>R67W</sup> cardiomyocytes (**Figure 6D**). On the other hand, compared to Kir2.1<sup>WT</sup>, peak I<sub>Na</sub>  
457 density was significantly reduced only in Kir2.1<sup>C122Y</sup> cardiomyocytes at baseline (**Figure**  
458 **6B**). However, whereas 10 μM flecainide reduced I<sub>Na</sub> density by ~48% in Kir2.1<sup>WT</sup>, the  
459 drug further decreased it in Kir2.1<sup>C122Y</sup> (~62%), and Kir2.1<sup>R67W</sup> (~66%) cardiomyocytes,  
460 showing a weaker effect over Kir2.1<sup>G215D</sup> (~52%) and Kir2.1<sup>S136F</sup> (~53%) cells (**Figure 6E-**  
461 **F**). These data further demonstrate that ATS1 mutants differentially modify I<sub>K1</sub> and I<sub>Na</sub>  
462 densities at baseline and under flecainide administration. Thus, our results reinforce the  
463 hypothesis that conduction disturbances and arrhythmias in ATS1 patients are not only  
464 due to I<sub>K1</sub> and RMP defects but also reduced excitability exacerbated by flecainide.  
465

#### 466 **ATS1 patient-specific iPSC-CMs are highly inducible for re-entrant arrhythmias**

467 We generated hiPSC-CM monolayers from consenting ATS1 patients carrying  
468 Kir2.1<sup>C122Y</sup>, Kir2.1<sup>R67W</sup> and Kir2.1<sup>G215D</sup> mutations (see *Supplementary Methods*). We  
469 conducted optical mapping experiments to validate our previous experiments and better  
470 understand the variable electrophysiological phenotypes of the patients in response to  
471 flecainide. Importantly, we used a CRISPR-mediated genetically corrected isogenic  
472 control (IC) for all three patient-specific hiPSC-CM to fully assess the contribution of Kir2.1  
473 mutations to arrhythmia. We carried out optical mapping experiments using the voltage-  
474 sensitive fluorescent dye FluoVolt in monolayers paced at basic cycle lengths (BCL)  
475 between 400 and 1000 ms. To better understand the underlying mechanism(s) of  
476 flecainide-induced arrhythmogenesis, mutant and IC monolayers were superfused with 5  
477 μM flecainide. CV restitution curves constructed from color phase maps displayed slower  
478 velocities in C122Y iPSC-CMs monolayers compared to IC. Impressively, the CV was  
479 highly reduced in C122Y monolayers after flecainide superfusion (**Figure 7B**).  
480 Additionally, flecainide induced non-sustained re-entrant activity with complete rotations  
481 followed by spontaneous termination in patient-specific Kir2.1<sup>C122Y</sup>, Kir2.1<sup>R67W</sup> and  
482 Kir2.1<sup>G215D</sup> iPSC-CMs (**Figure 7C**). Mutant iPSC-CMs monolayers were more inducible for  
483 re-entrant arrhythmias compared to ICs (6 out of 11, 54.5% in C122Y iPSC-CMs vs 2 out  
484 of 11, 18.2% in IC; 6 out of 11, 54.5% in R67W vs 3 out of 9, 33.3% in IC; 7 out of 11, 63.6%  
485 in G215D vs 5 out of 11, 45.5% in IC) (**Figure 7D**). Most importantly, flecainide  
486 superfusion resulted in an increased rate of rotor generation in C122Y, and R67W  
487 monolayers (rotors; 8 out of 11, 72.7% in C122Y vs 4 out of 14, 28.6% in IC; 8 out of 11,  
488 72.7% in R67W vs 2 out of 6, 33.3% in IC). However, while flecainide eliminated  
489 arrhythmias in IC monolayers (5 out of 11, or 45.5% rotors in untreated G215D IC vs 3 out  
490 of 10, or 30% rotors in flecainide-treated G215D IC), it did not alter arrhythmia inducibility  
491 in G215D iPSC-CMs; i.e., rotors were maintained during flecainide superfusion (7 out of  
492 11, 63.6% in non-treated G215D vs 7 out of 11, 63.6% in flecainide-treated cultures)  
493 (**Figure 7D**). Taken together, these data demonstrate that flecainide exacerbates the  
494 already abnormal conduction in patient-specific iPSC-CMs<sup>C122Y</sup> monolayers, leading to  
495 reentry and polymorphic tachycardia. However, the molecular mechanisms underlying  
496 arrhythmia inducibility and the ineffectiveness of flecainide in R67W and G215D iPSC-CM  
497 monolayers, respectively, remain unclear and suggest more complex mechanisms that  
498 are beyond the scope of this study.  
499

#### 500 **ATS1 mutations differentially alter flecainide-to-Kir2.1 molecular docking**

501 Previous computational studies have predicted that flecainide and propafenone  
502 share a common binding site within the tetrameric Kir2.1 channel determined by a  
503 pharmacophore involving Cys<sub>311</sub> in the cytosolic space.<sup>34</sup> However, it has not been  
504 determined whether Kir2.1 mutations may differentially reorganize the global structure of  
505 the Kir2.1 channel and destabilize the pharmacophore binding site determined by Cys<sub>311</sub>,  
506 interfering with flecainide binding. In line with this, recent findings show that the  
507 extracellular Cys<sub>122</sub>-to-Cys<sub>154</sub> disulphide bond breaks disrupt Kir2.1-PIP<sub>2</sub> interaction in the  
508 cytosolic-transmembrane region, which is distant from the location of the Kir2.1<sup>C122Y</sup>  
509 mutation.<sup>14</sup> To test the above hypothesis, we used *in-silico* molecular docking modeling to

510 derive predictions of the molecular interaction of the mutated Kir2.1<sup>C122Y</sup> channel and  
511 flecainide in the Cys<sub>311</sub>-mediated pharmacophore.

512 Our simulations revealed that Kir2.1<sup>WT</sup> channels exhibit a substantially enhanced  
513 binding affinity to flecainide in the presence of PIP<sub>2</sub>, which is crucial for stabilizing in the  
514 open state the narrowest part of the ion conduction pore (G-loop)<sup>36,37</sup>. Defects in PIP<sub>2</sub>  
515 binding are a major pathophysiological mechanism underlying the loss-of-function  
516 phenotype for several ATS1-associated mutations.<sup>9,38-40</sup> The atomic binding sites for  
517 flecainide and PIP<sub>2</sub> are closely located, and our simulation suggests that PIP<sub>2</sub> could help  
518 accommodate flecainide molecules. Accordingly, in the absence of PIP<sub>2</sub> flecainide failed  
519 to bind to Cys<sub>311</sub> in Kir2.1<sup>WT</sup> chains **c** and **d** in our simulations (**Figure 8A**). Impressively, a  
520 complete set of flecainide molecules (one per Kir2.1<sup>WT</sup> monomer) effectively integrated in  
521 the presence of PIP<sub>2</sub>, exhibiting enhanced binding energy compared to its absence  
522 (**Figure 8B**). This was evidenced by the Gibbs free-energy interface of flecainide binding  
523 in the presence of PIP<sub>2</sub> in chains **a** ( $\Delta dG$ -11.388) and **ab** ( $\Delta dG$ -12.868 for chain **a** and  
524  $\Delta dG$ -13.278 for chain **b**) vs chains **a** ( $\Delta dG$ -9.948) and **ab** ( $\Delta dG$ -9.979 for chain **a** and  
525  $\Delta dG$ -9.102 for chain **b**) in absence of PIP<sub>2</sub> (**Figure 8A-B**). Significantly, even though the  
526 Kir2.1<sup>C122Y</sup> mutation alters the PIP<sub>2</sub> binding pocket,<sup>14</sup> we observed that flecainide was fully  
527 incorporated into the heterozygous mutant channels with a total of 2 PIP<sub>2</sub> molecules (one  
528 per Kir2.1<sup>WT</sup> monomer) (**Figure 8C**).

529 However, the Solvent Accessible Surface Area (SASA) of each Cys<sub>311</sub>-  
530 pharmacophore in mutant C122Y heterotetramers exhibited significant variation along the  
531 contiguous chain as we introduced flecainide molecules, indicating a substantial decrease  
532 in the exposed surface area, which could potentially disrupt stable flecainide binding  
533 (**Figure 8D**). The incorporation of a second flecainide molecule in the mutant  
534 heterotetramer dramatically decreased the Gibbs free-energy of the firstly incorporated  
535 flecainide, as indicated the values for chains **a** ( $dG$  -13.24) and **ab** ( $\Delta dG$  -3.027 for chain **a**  
536 and  $\Delta dG$  -9.575 for chain **b**) (**Figure 8E**). Comparative analysis of channel properties  
537 revealed a similar pore length in WT (13.71 nm) and mutant (13.88 nm) heterotetramers,  
538 but with more than 40% reduction in maxRadius (5.69 nm in WT vs. 3.27 nm in mutant  
539 heterotetramer), suggesting channel constriction in the presence of flecainide (**Figure 8E**).  
540 In contrast, simulation of the Kir2.1<sup>S136F</sup> mutant heterotetramer did not disrupt the Cys<sub>311</sub>  
541 binding pocket, and flecainide successfully incorporated in mutant heterotetramers  
542 showing similar channel properties and binding capacity to the Kir2.1<sup>WT</sup> model (**Figure 8E-**  
543 **F**). Incorporation of a second flecainide molecule retained the Gibbs free-energy of the  
544 firstly incorporated flecainide for chains **a** ( $\Delta dG$  -14.601) and **ab** ( $\Delta dG$  -15.437 for chain **a**  
545 and  $\Delta dG$  -11.057 for chain **b**) (**Figure 8E**). Analysis of channel properties revealed a  
546 similar maxRadius (5.43 nm) and an increased pore length (16.86 nm) compared to the  
547 Kir2.1<sup>WT</sup> structure (**Figure 8F**).

548 Collectively, these *in silico* homology studies predict that the Cys<sub>311</sub> binding pocket  
549 is not conserved in mutant Kir2.1 channels. Depending on the specific mutation, the  
550 Cys<sub>311</sub> binding pocket may undergo unique atomic rearrangements that affect both the  
551 accessibility and energetic stability of flecainide molecules. This could potentially disrupt  
552 the dynamics of flecainide binding, leading to different outcomes for channel function  
553 depending on the particular ATS1 mutation.

## 554 555 Discussion

556 Flecainide received Food and Drug Administration (FDA) approval in 1984 for the  
557 treatment of sustained VT. Subsequently, the Cardiac Arrhythmia Suppression Trial  
558 (CAST) found that the drug was proarrhythmic and associated with excess all-cause  
559 mortality in patients with structural heart disease.<sup>41</sup> Since then, class-Ic AADs are  
560 contraindicated in patients with coronary heart disease or chronic congestive heart failure.  
561 Class-Ic AADs are potent Na<sup>+</sup> channel blockers that produce profound reductions in  
562 conduction velocity (CV)<sup>42,43</sup> and facilitate reentry, which explains their proarrhythmic  
563 effect.<sup>44</sup> These agents do not often suppress sustained VA induction by programmed  
564 stimulation.<sup>45,46</sup> They raise the defibrillation threshold in experimental models,<sup>47,48</sup> and their

565 use has been associated with incessant VT resistant to cardioversion.<sup>49,50</sup> On the other  
566 hand, both flecainide and propafenone have been indicated for supraventricular  
567 arrhythmias, including atrial fibrillation (AF). To the best of our knowledge, the mechanism  
568 has not been elucidated. Paradoxically, some investigators attribute such effects to  
569 chamber-specific differences with greater flecainide inhibition of atrial  $I_{Na}$ , leading to higher  
570 reduction of both maximum AP upstroke velocity and CV in atrial tissue.<sup>51</sup> Such an  
571 interpretation seems counter to the well-established knowledge that reduced maximum  
572 AP upstroke velocity and slowed conduction are pro-arrhythmic. Clinical and molecular  
573 evidence suggest that flecainide could potentially promote arrhythmias even in patients  
574 with structurally normal hearts, including reports of TdP and life-threatening PVT without  
575 coronary artery disease or heart failure.<sup>52,53</sup> Despite these risks, class-Ic AADs have been  
576 successfully used to treat hundreds of patients, and clinical guidelines continue to  
577 recommend them for specific arrhythmogenic cardiac diseases.<sup>7,8,54,55</sup>

578 ATS1 is a rare disease that may lead to life-threatening VA and SCD without  
579 affecting heart structure<sup>3</sup>. More than 90 ATS1-associated autosomal dominant mutations  
580 have been identified in the Kir2.1 protein. However, the molecular mechanisms are not  
581 fully understood, and variability in phenotype severity, even within the same family<sup>31</sup>,  
582 complicates treatment. Current antiarrhythmic therapies include  $\beta$ -blockers and class-Ic  
583 AADs. The use of  $\beta$ -blockers has been derived from an early view that considered ATS1  
584 as a variant of LQTS<sup>1</sup>, and from the assumption that patients would respond to  
585 antiadrenergic interventions, despite the lack of robust mechanistic underpinnings. In  
586 addition, a common treatment for ATS1 is flecainide or propafenone alone or in  
587 combination with  $\beta$ -blockers.<sup>56-59</sup> The use of class-Ic AADs in patients with ATS1 started  
588 with a report suggesting that flecainide effectively suppressed isolated PVCs and NSVT.<sup>60</sup>  
589 Since then clinical guidelines recommend combinations of  $\beta$ -blockers and traditional AADs  
590 like flecainide and propafenone.<sup>7,8</sup> However, their efficacy and safety in treating ATS1  
591 remain contentious, and emerging evidence suggests that they may be associated with  
592 variable efficacy and potential proarrhythmic effects.

593 To date, clinical guidelines fail to encourage standardization and homogeneity in  
594 defining VA and therapeutic success, as these vary significantly among reports,  
595 representing a major limitation of the available data. In support of this clinical observation,  
596 in our analysis of 53 ATS1 reported patients, flecainide and propafenone showed partial  
597 effectiveness. As illustrated in **Table 1**, several brief reports have suggested that  
598 flecainide, alone or in combination with  $\beta$ -blockers suppresses VA in ATS1  
599 patients.<sup>4,57,58,60-72</sup> One study reported a 54-year-old male carrying the Kir2.1<sup>V302M</sup> mutation  
600 who experienced over 98% reduction in the number of PVCs (from a total of 15671 in 24h  
601 Holter monitoring) following flecainide treatment (200mg/day).<sup>62</sup> However, a careful review  
602 of clinical data from 48 patients showed a large patient-to-patient variability, mostly with  
603 incomplete disappearance of VA under flecainide, which did not prevent life-threatening  
604 arrhythmias and SCD (**Table 1**).<sup>4,57,62,64,73</sup> In a case report of a 15-year-old boy carrying  
605 the Kir2.1<sup>R218W</sup> mutation, flecainide, mexiletine or nadolol monotherapy was ineffective in  
606 preventing or reducing VA; only a combination of flecainide with verapamil reduced the  
607 number of PVCs by about 87% (from 40846 per day).<sup>64</sup> In contrast, patients experienced  
608 more moderate responses to flecainide alone. For example, ATS1 probands with the  
609 Kir2.1<sup>R67Q</sup> mutation showed only about 44% VA reduction (from a total of 19389 to 10854  
610 PVCs) under flecainide (100 mg/day) combined with atenolol (50mg/day).<sup>73</sup> Additionally,  
611 Miyamoto et al. reported that oral flecainide (100-200 mg/day) reduced VA in 10 patients,  
612 who still maintained a ~30% VA burden.<sup>41</sup> Several reports have shown that class-Ic  
613 AADs like flecainide and propafenone are ineffective in suppressing VA in ATS1.<sup>4,14,74-78</sup> In  
614 one case, propafenone was ineffective even when combined with verapamil, as the  
615 proband still presented frequent episodes of bigeminy<sup>75</sup>. Importantly, some studies have  
616 reported cases of aborted SCD in patients with ATS1 who received an external  
617 defibrillation or an ICD shock under treatment with flecainide or propafenone.<sup>4,14,60,72,74,77</sup>  
618 Although flecainide was effective in reducing the high burden of VA in one patient,  
619 Bokenkamp et al. reported one appropriate ICD shock for Torsades de Pointes (TdP)

620 tachycardia after three years under flecainide. In contrast, the patient's sister was  
621 asymptomatic carrying the same Kir2.1<sup>R218W</sup> mutation.<sup>60</sup> In the series of Delannoy et al,  
622 one patient experienced a non-fatal cardiac arrest related to NSVT despite  $\beta$ -blockers and  
623 flecainide treatment.<sup>77</sup> Similarly, Mazzanti et al. reported that the combination of these  
624 drugs usually fails to reduce arrhythmias in ATS1.<sup>4</sup> Interestingly, in Mazzanti's series 2 out  
625 of 12 monitored probands experienced non-fatal cardiac arrest while on treatment<sup>4</sup>, but it  
626 remains unclear whether this was due to proarrhythmia or merely ineffective therapy.

627 In our analysis, more than 20 loss-of-function Kir2.1 mutations were associated  
628 with highly variable phenotypes (**Table 1**). This suggests that the molecular mechanisms  
629 underlying the increased susceptibility to arrhythmias and SCD in ATS1 patients may  
630 differ based on the specific mutation, which is crucial in determining the response to  
631 AADs. In addition, our animal and human cell experiments reinforce the idea that ion  
632 channel interactions within multiprotein complexes, including Kir2.1-Na<sub>v</sub>1.5  
633 channelosomes, likely contribute to the wide variety of clinical outcomes.<sup>31,79-81</sup> Therefore,  
634 the molecular and functional interactions between Kir2.1-Na<sub>v</sub>1.5 indicates that ATS1  
635 should no longer be considered in simplistic terms as a "monogenic" disorder. Reduction  
636 in I<sub>K1</sub> may directly affect the functional expression or biophysical properties of Na<sub>v</sub>1.5  
637 channels. I<sub>K1</sub> reduction depolarizes the RMP and reduces the availability of Na<sub>v</sub>1.5 for  
638 activation, with consequent impairment of cellular excitability and CV.<sup>82-84</sup> However, recent  
639 studies have shown that some mutation can also directly impact I<sub>Na</sub> density, adding  
640 another layer of complexity to the electrophysiological alterations in ATS1. For instance,  
641 the trafficking-deficient Kir2.1<sup>A314-315</sup> mutation and the Kir2.1<sup>C122Y</sup> mutant that affects Kir2.1-  
642 PIP<sub>2</sub> interactions reduce Kir2.1 and Na<sub>v</sub>1.5 protein levels at the cell membrane interfering  
643 with both I<sub>K1</sub> and I<sub>Na</sub> densities in the cardiomyocyte. Both mutations lead to a slow-  
644 conduction substrate favorable for cardiac arrhythmias.<sup>23,14</sup> The balance between I<sub>Na</sub> and  
645 I<sub>K1</sub> is a key determinant of the frequency and stability of ventricular rotors that ultimately  
646 generate cardiac fibrillation and lead to SCD.<sup>85</sup> This delicate balance could be disrupted  
647 by some ATS1 mutations at baseline and further exacerbated by class-Ic AADs.  
648 Therefore, pharmacological treatment and clinical management should be carefully  
649 tailored based on the specific mutation and individualized for each patient. However,  
650 to our knowledge, no previous studies have evaluated the proarrhythmogenic consequences  
651 of ATS1 and their impact on cardiac electrophysiology in response to class-Ic AADs.

652 Our finding revealed that flecainide and propafenone differentially prolonged the P  
653 wave duration and the PR, QRS and QTc intervals. They also increased VA inducibility  
654 compared with Kir2.1<sup>WT</sup>. In addition, flecainide promoted spontaneous VA and conduction  
655 disturbances of varying types (**Figure 4**), including NSVT, atrioventricular (AV) block, and  
656 long-short coupling PVCs, which have been previously associated with Purkinje fiber  
657 dysfunction.<sup>86</sup> Altogether, these observations support the presence of different mutant-  
658 dependent mechanism, consistent with our hypothesis. Further, voltage-clamp  
659 experiments revealed that flecainide increased I<sub>K1</sub> density in Kir2.1<sup>WT</sup> cardiomyocytes, as  
660 previously described in HEK293 cells.<sup>34,35</sup> However, in support of our hypothesis, the  
661 effects of flecainide were different in cardiomyocytes expressing mutant channels (**Figure**  
662 **6**). While Kir2.1<sup>S136F</sup> responded similar to Kir2.1<sup>WT</sup>, flecainide resulted ineffective in  
663 recovering the already decreased I<sub>K1</sub> of Kir2.1<sup>G215D</sup> cardiomyocytes. Interestingly, in both  
664 Kir2.1<sup>R67W</sup> and Kir2.1<sup>C122Y</sup>, I<sub>K1</sub> density was significantly reduced both under basal  
665 conditions and in the presence of flecainide, which emphasizes I<sub>K1</sub> blockade as a pro-  
666 arrhythmic mechanism of flecainide and a possible mechanism for prolonged QTc.  
667 Similarly, the class III AAD amiodarone blocks I<sub>K1</sub><sup>87</sup> and likely reduces excitability by  
668 depolarizing the RMP giving a rationale for an increased risk of life-threatening arrhythmic  
669 events in ATS1 patients. As Mazzanti et al also suggested, amiodarone may be pro-  
670 arrhythmic and should be avoided in ATS1 patients.<sup>4</sup> Flecainide also exacerbated the  
671 reduction of I<sub>Na</sub> density despite normal channel trafficking in Kir2.1<sup>C122Y</sup> and Kir2.1<sup>R67W</sup>, and  
672 with great dispersion in Kir2.1<sup>G215D</sup> mutant cardiomyocytes, which suggests heterogeneity  
673 that contributes to proarrhythmia. Accordingly, in ATS1 patient-specific iPSC-CM  
674 monolayers flecainide reduced CV in C122Y monolayers. Nevertheless, based on the

675 above findings, flecainide was ineffective in modifying the high rotor incidence in G215D  
676 cultures compared to baseline but increased in C122Y and R67W, supporting the drug's  
677 proarrhythmic effect.

678 Flecainide was originally characterized as a potent Na<sup>+</sup> channel blocker that  
679 produce profound reductions in conduction velocity (CV),<sup>42,43</sup> but flecainide can also affect  
680 ionic currents governing ventricular repolarization,<sup>88-91</sup> although the molecular  
681 mechanisms are poorly understood. Clinical observations support the notion that cardiac  
682 electrical instability during flecainide treatment may be determined by defects in  
683 ventricular repolarization.<sup>92-95</sup> Flecainide blocks the transient outward K<sup>+</sup> current (I<sub>to</sub>) in a  
684 concentration-dependent manner, and some experimental studies attribute its  
685 proarrhythmic effect in structurally normal hearts to increased spatial repolarization  
686 gradients<sup>96</sup> brought about by varying I<sub>to</sub> expression across the myocardial wall.<sup>97</sup> But,  
687 flecainide can also induce arrhythmia by increasing repolarization heterogeneities at the  
688 level of the Purkinje fiber-ventricular muscle junction<sup>98</sup>. Non-uniform expression of the  
689 delayed rectifier K<sup>+</sup> channels throughout the ventricular epicardium may also contribute to  
690 dissimilar flecainide-induced APD lengthening in the left vs right ventricles.<sup>99,100</sup> In  
691 addition, flecainide modulates ryanodine receptor type 2 (RyR2) activity and inhibits the  
692 RyR2 open state to prevent diastolic Ca<sup>2+</sup> waves that trigger arrhythmias.<sup>7,101,102</sup>  
693 Flecainide might also modify the recently demonstrated SR microdomain of functional  
694 Kir2.1 channels<sup>103</sup> that provide countercurrent to SERCA-mediated Ca<sup>2+</sup> influx, potentially  
695 altering Ca<sup>2+</sup> handling, which may contribute to proarrhythmia in ATS1.<sup>23</sup> More studies  
696 would be needed to assess the mutant-dependent contribution on Ca<sup>2+</sup> homeostasis and  
697 VA in flecainide-treated ATS1 patients.

698 While flecainide and propafenone interact with Cys<sub>311</sub> in the Kir2.1<sup>WT</sup> subunits and  
699 reduce polyamine-induced inward rectification, it remains unclear how mutant ATS1  
700 channels impact the Cys<sub>311</sub> pharmacophore. Our in-silico molecular docking experiments  
701 indicate that, unlike Kir2.1<sup>WT</sup> channels, the Cys<sub>311</sub> binding pocket is not conserved in ATS1  
702 mutant heterotetramers. This might disrupt the dynamic maintenance of flecainide binding  
703 with unexpected consequences, potentially leading to channel closure and arrhythmias in  
704 a subset of mutant channels, as we observed *in-vivo*. Interestingly, our in-silico studies  
705 also predict that the Kir2.1-PIP<sub>2</sub> interaction energetically stabilizes the binding of flecainide  
706 to the Kir2.1 channel. These findings suggest that mutations like C122Y, R67W, and  
707 G215D that disrupt Kir2.1-PIP<sub>2</sub> interactions<sup>9,14</sup> could result in less favorable outcomes  
708 compared to mutations like S136F, which do not interfere with this interaction but affect  
709 filter-selectivity properties.<sup>9,31,32</sup> However, further studies are required to elucidate  
710 whether mutation-induced disruption of Kir2.1-PIP<sub>2</sub> interactions is a key factor in the pro-  
711 arrhythmogenic effects of flecainide, which would lead to its contraindication in patients  
712 carrying such mutations. Studies should also explore the molecular effects of  
713 incorporating others AADs alone or in combination with β-adrenergic blocking drugs.

714 The results of our study underscore the need for a cautious re-evaluation of class-  
715 Ic AADs in ATS1 patients to achieve optimal treatment outcomes and minimize adverse  
716 effects. Our results suggest that Kir2.1 mutations should not only be classified according  
717 to their location in the channel structure but also based on their functional implications at  
718 the subcellular and cellular levels. In this sense, cardiac excitability is likely to be  
719 dramatically reduced in ATS1 patients carrying the trafficking-deficient Kir2.1<sup>Δ314-315</sup>  
720 mutation, for whom we suggest direct exclusion of sodium channel blockers like flecainide  
721 and propafenone, because of the high risk of arrhythmias. The same would be expected  
722 for the Kir2.1<sup>C122Y</sup> mutation which, despite reaching the sarcolemma, its structural changes  
723 lead to its Kir2.1-Na<sub>v</sub>1.5 channelosome degradation.<sup>14</sup> Conversely, patients carrying  
724 mutations like Kir2.1<sup>S136F</sup>, which does not reduce excitability and CV, might benefit from  
725 the use of currently available AADs as demonstrated. In other words, a specific  
726 combination of β-blockers and flecainide might be appropriate for ATS1-causing mutations  
727 that alter the conformation of the channel, but not for mutations that affect Kir2.1  
728 trafficking or others that lead to a decrease in I<sub>Na</sub> density.

729



730 **Limitations**

731 Like any other rare disease, implementing evidence-based therapeutic  
732 interventions for ATS1 presents significant challenges. Conducting conventional  
733 randomized controlled trials on ATS1 is particularly difficult due to the minimal number of  
734 patients worldwide. Unfortunately, the reported data often lack uniformity in key details,  
735 such as treatment duration, dosages and routes of administration. As such, after  
736 exhaustively searching the literature, we summarized data from only 23 publications  
737 containing isolated ATS1 case reports or small series without follow-up. Our study is  
738 limited to assessing the effects of an empirical, “one-size-fits-all” antiarrhythmic treatment  
739 of patients of both genders, all age ranges and diverse origins based on flecainide and  
740 other class-Ic AADs. Such limitations notwithstanding, we demonstrate that the cardiac  
741 electrical response of ATS1 patients to class-Ic AADs is highly variable, and at times  
742 contrary to anticipated. While some patients benefit from the use of these drugs, others do  
743 not, and yet others may get worse. The results support our hypothesis that the effect of  
744 class-Ic AAD treatment in a given ATS1 patient will depend on the precise  
745 electrophysiological consequences of the Kir2.1 loss-of-function mutation. The hypothesis  
746 is further supported by experiments in a small but highly relevant group of mutant mouse  
747 models, iPSC-CMs from three different ATS1 patients and in-silico simulations  
748 demonstrating a significant hierarchy in the mutation-induced arrhythmic phenotype and  
749 molecular effects in response to flecainide treatment. While well outside of the scope of  
750 this study, we are well aware of the need to assess the role of channels other than Kir2.1  
751 and Na<sub>v</sub>1.5 and the effects of spatial heterogeneities to establish more rigorously the  
752 mechanisms of mutation-induced arrhythmias and their exacerbation by the drugs.  
753 Nevertheless, our experimental results strongly support that flecainide-induced pro-  
754 arrhythmia might be at least in part due to specific reductions in both I<sub>K1</sub> and I<sub>Na</sub>, which  
755 significantly impairs excitability as demonstrated by the prolongation of the PR and QRS  
756 intervals in the mutant mice and the slowing of CV in the mutant iPSC-CMs.

757  
758 **Conclusion**

759 The results presented here open new horizons for the pharmacologic management  
760 of ATS1 patients. They demonstrate for the first time that whether or not class-Ic AADs  
761 will benefit a given ATS1 patient will depend on the precise electrophysiological  
762 consequences of specific Kir2.1 mutation. As such, we must no longer correct only the  
763 lack of function of the mutated channel, but also consider the possible repercussions on  
764 the molecular interactors of the channel that each particular mutation entails. A deeper  
765 understanding of the different arrhythmogenic mechanisms associated with different ATS1  
766 mutations should open new pathways for personalized treatments of patients suffering  
767 from these devastating channelopathies. Our results emphasize the need to gain a deeper  
768 understanding of the specific pharmacologic regulation of Kir2.1 mutations, elucidate the  
769 pathophysiology of arrhythmias in individual patients with ATS1, and identify an effective,  
770 more personalized therapy that reduces individual proarrhythmia risk. Therefore, studies  
771 on the usefulness of already approved drugs and their derivatives for the treatment of  
772 diseases such as ATS1 should continue to improve the stratification of affected patients.  
773

774 **ACKNOWLEDGEMENTS**

775 We thank the CNIC Viral Vectors Unit for producing the AAV9. Confocal experiments were  
776 conducted at the CNIC Microscopy and Dynamic Imaging Unit. We thank the CNIC  
777 Bioinformatics Unit for generating the *in-silico* homology modeling simulations, F-function  
778 analysis, and helpful discussions. We also thank the Centro de Supercomputación de  
779 Galicia (CESGA) for the use of the Finis Terrae III supercomputer to perform molecular  
780 dynamics studies. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the  
781 Ministerio de Ciencia, Innovación y Universidades (MICIU), and the Pro CNIC Foundation,  
782 and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by  
783 MICIN/AEI/10.13039/501100011033).

784  
785 **FUNDING:** Supported by National heart, Lung and Blood Institute, NIH grant number  
786 R01HL163943; La Caixa Banking Foundation project code HR18-00304  
787 (LCF/PR/HR19/52160013); grants PI-FIS-2020 # PI20/01220 and PI-FIS-2023 #  
788 PI23/01039 from Instituto de Salud Carlos III (ISCIII) and co-funded by Fondo Europeo de  
789 Desarrollo Regional (FEDER), and by The European Union, respectively; grant PID2020-  
790 116935RB-I00 and BFU2016-75144-R funded by MCIN/AEI/10.13039/501100011033;  
791 Fundación La Marató de TV3 (736/C/2020) “*amb el suport de la Fundació La Marató de*  
792 *TV3*”; CIBERCV (CB16/11/00458; CB/11/00222 to CV); European Union's Horizon 2020  
793 grant agreement GA-965286; and Program S2022/BMD7229 -CM ARCADIA-CM funded  
794 by Comunidad de Madrid; to JJ; Program S2022/BMD-7223 funded by Comunidad de  
795 Madrid, to CV; Grant PID2022-137214OB-C21 (to CV), funded by  
796 MCIN/AEI/10.13039/501100011033; The imaging studies were performed in the  
797 TRIMA@CNIC node of the ICTS ReDIB Grant ICTS-2018-04-CNIC-16 funded by  
798 MCIN/AEI /10.13039/501100011033 and ERDF; project EQC2018-005070-P funded by  
799 MCIN/AEI /10.13039/501100011033 and FEDER. AIM-M holds an FPU contract  
800 (FPU20/01569) from Ministerio de Universidades. JMRR holds an FPU contract  
801 (FPU22/03253) from Ministerio de Universidades. LKG holds an FPI contract (PRE2018-  
802 083530), Ministerio de Economía y Competitividad de España co-funded by Fondo Social  
803 Europeo, attached to Project SEV-2015-0505-18-2. IMC holds a PFIS contract  
804 (FI21/00243) funded by Instituto de Salud Carlos III and Fondo Social Europeo Plus  
805 (FSE+), ‘co-funded by the European Union’. MLVP held contract PEJD-2019-PRE/BMD-  
806 15982 funded by Consejería de Educación e Investigación de la Comunidad de Madrid y  
807 Fondo Social Europeo.

808

809 **DISCLOSURES**

810 None

811

812 **AUTHOR CONTRIBUTION**

813 F.M.C. and J.J. co-designed the experiments; F.M.C. performed most of the experiments;  
814 A.I.M.M. and P.G.S. are authors for cellular electrophysiology; E.Z., and J.J.J. provided  
815 clinical data, discussion and revisions; F.M. were in charge of in-silico homology modeling  
816 and molecular docking studies; P.S.P., M.L.V. and A.T.G. cultivated iPSC-CMs cells;  
817 L.K.G. and J.R.R performed optical mapping analysis; A.M., G.M.P., S.A.S., I.M.C., F.B.J.,  
818 A.B.B., C.V. provided technical support, discussions and revisions; F.M.C. and J.J. co-  
819 wrote the manuscript and conceived the study; J.J. provided funding; J.J. provided  
820 supervision and revisions; All authors discussed the results and commented on and  
821 approved the manuscript.

822

823 **CORRESPONDING AUTHORS**

824 Correspondence to José Jalife or Francisco M. Cruz.

825

826 **SUPPLEMENTAL INFORMATION**

827 Extended Materials & Methods

828 Supplementary Figures 1-2

829 Supplementary Tables 1-2

## 830 **Figures legends**

### 831 **Table 1: Response to class-Ic AADs in ATS1 patients.**

832 Detailed analysis of 53 different probands shows a large variability from patient to patient.  
833 Data reveal moderate, incomplete or ineffective responses to class-Ic AADs in  
834 suppressing ventricular arrhythmias (VA) in ATS1. The table incorporates demographic  
835 information and clinical features of reviewed ATS1 cases, including age, sex, reported  
836 mutation, cardiac phenotype, treatment, and response.  
837

### 838 **Figure 1. Arrhythmogenic responses to Ic class AADs in ATS1 patients**

839 **A:** Recorded polymorphic ventricular tachycardia (VT) from an automated external  
840 defibrillator in Kir2.1<sup>C122Y</sup> proband (II.2). Pedigree of the family is shown in the upper left  
841 square. **B:** Recorded polymorphic ventricular tachycardia (*upper panel*) and a high burden  
842 of non-sustained ventricular tachycardias (NSVT) in Kir2.1<sup>G215D</sup> proband (I.2) under  
843 Flecainide + Nadolol (*middle panel*) or Propafenone + Nadolol (*bottom panel*). **C:** ECG  
844 from Kir2.1<sup>R67W</sup> patient shows polymorphic VT. All Probands are indicated with a black  
845 arrow.  
846

846

### 847 **Figure 2. Class-Ic-based antiarrhythmic therapy in AST1.**

848 **A-B:** Venn diagram (**A**) and schematic representation (**B**) of class-Ic therapy response in  
849 ATS1 patients. Data show 23% of patients who benefited from a full or greater than 90%  
850 suppression of VA; 54% reported substantial but incomplete improvement during  
851 flecainide treatment, mostly maintaining 20 to 50% of VA. In 23% of patients, flecainide  
852 was completely ineffective; 13.5% experienced an additional non-fatal cardiac arrest with  
853 an appropriate ICD shock in the presence of flecainide.  
854

854

### 855 **Figure 3. ATS1 mice recapitulate the pathological ECG phenotype**

856 **A-B:** Time-course after a single dose of flecainide (**A**) or propafenone (40 mg/Kg) (**B**)  
857 reveals prolonged P wave, PR, QRS and QTc in Kir2.1 mutant animals compared to  
858 controls (black). Every value represents the averaged P waves, PR, QRS and QTc  
859 intervals from ten consecutive beatings. Arrows indicate the time of  
860 flecainide/propafenone administration. Representative beats of Kir2.1<sup>WT</sup> (black), Kir2.1<sup>Δ314-</sup>  
861 <sup>315</sup> (green), Kir2.1<sup>C122Y</sup> (red), Kir2.1<sup>G215D</sup> (purple), Kir2.1<sup>R67W</sup> (blue) and Kir2.1<sup>S136F</sup> (orange)  
862 mice after 5 min of flecainide administration are also indicated. Statistical analysis by two-  
863 tailed ANOVA. \* = p<0.05; \*\* = p<0.01; \*\*\*\* = p<0.0001.  
864

864

### 865 **Figure 4. Flecainide is proarrhythmic and alters cardiac conduction in ATS1 mice**

866 Representative electrocardiograms (ECG) lead-II traces recordings in AAV-transduced  
867 Kir2.1<sup>C122Y</sup> (**A**) animals showing frequent premature ventricular complexes (PVCs),  
868 Kir2.1<sup>G215D</sup> (**B**) and Kir2.1<sup>Δ314-315</sup> (**C**) animals showing atrioventricular block, and Kir2.1<sup>R67W</sup>  
869 (**D**) animals showing non-sustained ventricular tachycardia (NSVT) after flecainide  
870 administration.  
871

871

### 872 **Figure 5. Flecainide increases susceptibility to arrhythmias in ATS1 mutant mice.**

873 **A:** Representative ECG lead-II traces after a train of intracardiac ventricular pulses in  
874 AAV-transduced Kir2.1<sup>WT</sup> (black; N=10), Kir2.1<sup>Δ314-315</sup> (green; N=8), Kir2.1<sup>C122Y</sup> (red; N=8),  
875 Kir2.1<sup>G215D</sup> (purple; N=6), Kir2.1<sup>R67W</sup> (blue; N=6) and Kir2.1<sup>S136F</sup> (orange; N=8) animals with  
876 periods of polymorphic ventricular tachycardia (PVT) at baseline. A short duration of non-  
877 sustained ventricular tachycardias (NSTV) is indicated. **B:** Contingency plots showing the  
878 number of animals with the arrhythmogenic response after intracardiac stimulation at  
879 baseline (top) and under flecainide (20mg/Kg) (bottom). **C:** Representative ECG lead-II  
880 trace showing longer NSVT runs after flecainide administration. **D:** Graph shows  
881 ventricular tachycardias (VT) duration at baseline and under flecainide administration.  
882 Statistical analysis using the Fisher's exact test. \* = p<0.05; \*\* = p<0.01; \*\*\* = p<0.001;  
883 \*\*\*\* = p<0.0001

884

885 **Figure 6. Cardiac expression of ATS1 mutations alter mouse ventricle**  
886 **electrophysiology in isolated cardiomyocytes.**

887 **A:** Current-voltage (I/V) relationships of inward rectifying potassium current  $I_{K1}$  and **B:**  $I_{Na}$   
888 density in Kir2.1<sup>WT</sup> (black), Kir2.1<sup>Δ314-315</sup> (green), Kir2.1<sup>C122Y</sup> (red), Kir2.1<sup>G215D</sup> (purple),  
889 Kir2.1<sup>R67W</sup> (blue) and Kir2.1<sup>S136F</sup> (orange) cardiomyocytes at baseline and under flecainide  
890 superfusion. **C:**  $I_{K1}$  slope from -140 to -60 mV at baseline and under flecainide  
891 administration. **D:** Sodium density  $I_{Na}$  peak (pA/pF) at -35mV. **E:** Percentage of remaining  
892  $I_{Na}$  density after flecainide inhibition. Statistical analyses were conducted using two-tailed  
893 ANOVA. \* = p<0.05; \*\* = p<0.01; \*\*\*\* = p<0.0001.

894

895 **Figure 7. Flecainide leads to conduction defects and re-entrant arrhythmias in**  
896 **patient-specific iPSC-CMs.**

897 **A:** Representative single camera pixel recording from an optical mapping experiment  
898 show velocity maps with 1 ms activation isochrones in patient-specific iPSC-CMs<sup>C122Y</sup>  
899 (red) and CRISPR-mediated isogenic control iPSC-CMs<sup>C122Y</sup> (blue) hearts paced at a  
900 basic cycle length (BCL) of 400 ms. The color bar indicates conduction velocity (CV; cm s-  
901 1). The white asterisks indicate the pacing point and the propagation direction is indicated  
902 by the white arrow. **B:** Re-entrant arrhythmias from C122Y, G215D and R67W patient-  
903 specific iPSC-CMs monolayers under flecainide treatment. Below each map is a single  
904 pixel recording revealing different patterns of monomorphic or polymorphic re-entrant  
905 tachycardia maintained by one self-sustaining rotor. **C:** The CV restitution curve displayed  
906 slower velocities in iPSC-CMs<sup>C122Y</sup> monolayers at all frequencies tested. All groups  
907 presented slightly slower velocities at higher frequencies. Each value is the mean ± SEM  
908 (N=5 differentiations; n indicates number of monolayers per condition; two-way ANOVA  
909 corrected by Tukey's multiple comparisons test, \* p<0.05; \*\* p<0.01; a=IC C122Y vs  
910 C122Y; b= IC C122Y Fleca vs C122Y Fleca; c= IC C122Y vs 122Y Fleca; and d= IC 122Y  
911 vs IC C122Y Fleca). **D:** Contingency plots of number of monolayers show arrhythmia  
912 inducibility for each group. Data show a high rate of arrhythmia susceptibility in mutant  
913 iPSC-CMs. Each value is the mean ± SEM (Fisher's exact test for contingency data).

914

915 **Figure 8. Kir2.1 mutated channels display conformational alteration in the**  
916 **pharmacophore binding site at Cys<sub>311</sub>.**

917 **A:** Tridimensional (3D) representation of Kir2.1<sup>WT</sup> showing cavities C (magenta) and D  
918 (yellow) in the absence (top) and presence (bottom) of PIP<sub>2</sub> molecules. Note that PIP<sub>2</sub> is  
919 required for proper flecainide binding in **c** and **d** cavities. PIP<sub>2</sub> (red arrow) and flecainide  
920 (blue arrow) are also indicated. **B:** 3D representation of flecainide binding in cavity **a**  
921 (green) and **b** (blue) in the absence (top) and presence (bottom) of PIP<sub>2</sub> molecules in  
922 Kir2.1<sup>WT</sup>. Gibbs free energy values are shown, being more stable in the presence of PIP<sub>2</sub>.  
923 **C:** 3D representation of flecainide binding in Kir2.1<sup>C122Y</sup> heterotetramer. Flecainide is fully  
924 present in Kir2.1<sup>C122Y</sup> heterotetramer. **D:** Solvent Accessible Surface Area (SASA) of each  
925 Cys<sub>311</sub>-pharmacophore in Kir2.1<sup>WT</sup> (blue) and Kir2.1<sup>C122Y</sup> (red) in sequential incorporation  
926 flecainide molecules. **E:** Comparative table of Gibbs free energy values of flecainide  
927 binding to each chain in Kir2.1<sup>WT</sup>, Kir2.1<sup>C122Y</sup> and Kir2.1<sup>S136F</sup> channels. **F:** Schematic  
928 representation of Kir2.1<sup>WT</sup> (top), Kir2.1<sup>C122Y</sup> (middle) and Kir2.1<sup>S136F</sup> (bottom) channel  
929 showing a similar pore length (13.71 nm; 13.88 nm; and 16.86 nm) and maxRadius (5.69  
930 nm; 3.27 nm; and 5.43 nm), respectively.

931

932 **References**

933

- 934 1 Tristani-Firouzi, M. *et al.* Functional and clinical characterization of KCNJ2  
935 mutations associated with LQT7 (Andersen syndrome). *J Clin Invest* **110**, 381-388,  
936 doi:10.1172/JCI15183 (2002).
- 937 2 Pegan, S., Arrabit, C., Slesinger, P. A. & Choe, S. Andersen's syndrome mutation  
938 effects on the structure and assembly of the cytoplasmic domains of Kir2.1.  
939 *Biochemistry* **45**, 8599-8606, doi:10.1021/bi060653d (2006).
- 940 3 Tristani-Firouzi, M. & Etheridge, S. P. Kir 2.1 channelopathies: the Andersen-Tawil  
941 syndrome. *Pflugers Arch* **460**, 289-294, doi:10.1007/s00424-010-0820-6 (2010).
- 942 4 Mazzanti, A. *et al.* Natural History and Risk Stratification in Andersen-Tawil  
943 Syndrome Type 1. *J Am Coll Cardiol* **75**, 1772-1784, doi:10.1016/j.jacc.2020.02.033  
944 (2020).
- 945 5 Priori, S. G. *et al.* 2015 ESC Guidelines for the management of patients with  
946 ventricular arrhythmias and the prevention of sudden cardiac death: The Task  
947 Force for the Management of Patients with Ventricular Arrhythmias and the  
948 Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC).  
949 Endorsed by: Association for European Paediatric and Congenital Cardiology  
950 (AEPC). *European heart journal* **36**, 2793-2867, doi:10.1093/eurheartj/ehv316  
951 (2015).
- 952 6 Richards, S. *et al.* Standards and guidelines for the interpretation of sequence  
953 variants: a joint consensus recommendation of the American College of Medical  
954 Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*  
955 **17**, 405-424, doi:10.1038/gim.2015.30 (2015).
- 956 7 Zeppenfeld, K. *et al.* 2022 ESC Guidelines for the management of patients with  
957 ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J*  
958 **43**, 3997-4126, doi:10.1093/eurheartj/ehac262 (2022).
- 959 8 Al-Khatib, S. M. *et al.* 2017 AHA/ACC/HRS guideline for management of patients  
960 with ventricular arrhythmias and the prevention of sudden cardiac death: A  
961 Report of the American College of Cardiology/American Heart Association Task  
962 Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*  
963 **15**, e73-e189, doi:10.1016/j.hrthm.2017.10.036 (2018).
- 964 9 Moreno-Manuel, A. I. *et al.* Molecular stratification of arrhythmogenic  
965 mechanisms in the Andersen Tawil syndrome. *Cardiovasc Res* **119**, 919-932,  
966 doi:10.1093/cvr/cvac118 (2023).
- 967 10 Matamoros, M. *et al.* Nav1.5 N-terminal domain binding to alpha1-syntrophin  
968 increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels.  
969 *Cardiovasc Res* **110**, 279-290, doi:10.1093/cvr/cvw009 (2016).
- 970 11 Ponce-Balbuena, D. *et al.* Cardiac Kir2.1 and Nav1.5 Channels Traffic Together to  
971 the Sarcolemma to Control Excitability. *Circ Res* **122**, 1501-1516,  
972 doi:10.1161/CIRCRESAHA.117.311872 (2018).
- 973 12 Utrilla, R. G. *et al.* Kir2.1-Nav1.5 Channel Complexes Are Differently Regulated  
974 than Kir2.1 and Nav1.5 Channels Alone. *Front Physiol* **8**, 903,  
975 doi:10.3389/fphys.2017.00903 (2017).
- 976 13 Ma, D. *et al.* Golgi export of the Kir2.1 channel is driven by a trafficking signal  
977 located within its tertiary structure. *Cell* **145**, 1102-1115, doi:S0092-  
978 8674(11)00649-0 [pii]  
979 10.1016/j.cell.2011.06.007 (2011).

- 980 14 Cruz, F. M. *et al.* Extracellular Kir2.1(C122Y) Mutant Upsets Kir2.1-PIP(2) Bonds  
981 and Is Arrhythmogenic in Andersen-Tawil Syndrome. *Circ Res* **134**, e52-e71,  
982 doi:10.1161/CIRCRESAHA.123.323895 (2024).
- 983 15 Tamargo, J., Delpón, E. in *Cardiac Electrophysiology. 6th edn.* (ed D. Zipes, Jalife,  
984 J.) 529-540 (2014).
- 985 16 Kimura, H. *et al.* Phenotype variability in patients carrying KCNJ2 mutations. *Circ*  
986 *Cardiovasc Genet* **5**, 344-353, doi:10.1161/CIRCGENETICS.111.962316  
987 CIRCGENETICS.111.962316 [pii] (2012).
- 988 17 Xiao, X., Li, J. & Samulski, R. J. Production of high-titer recombinant adeno-  
989 associated virus vectors in the absence of helper adenovirus. *J Virol* **72**, 2224-  
990 2232, doi:10.1128/JVI.72.3.2224-2232.1998 (1998).
- 991 18 Hauswirth, W. W., Lewin, A. S., Zolotukhin, S. & Muzyczka, N. Production and  
992 purification of recombinant adeno-associated virus. *Methods Enzymol* **316**, 743-  
993 761, doi:10.1016/s0076-6879(00)16760-6 (2000).
- 994 19 Cruz, F. M. *et al.* Exercise triggers ARVC phenotype in mice expressing a disease-  
995 causing mutated version of human plakophilin-2. *J Am Coll Cardiol* **65**, 1438-1450,  
996 doi:S0735-1097(15)00445-3 [pii]  
997 10.1016/j.jacc.2015.01.045 (2015).
- 998 20 Cerrone, M. *et al.* Sodium current deficit and arrhythmogenesis in a murine model  
999 of plakophilin-2 haploinsufficiency. *Cardiovasc Res* **95**, 460-468,  
1000 doi:10.1093/cvr/cvs218  
1001 cvs218 [pii] (2012).
- 1002 21 Heath, B. M. *et al.* Translation of flecainide- and mexiletine-induced cardiac  
1003 sodium channel inhibition and ventricular conduction slowing from nonclinical  
1004 models to clinical. *J Pharmacol Toxicol Methods* **63**, 258-268,  
1005 doi:10.1016/j.vascn.2010.12.004 (2011).
- 1006 22 Bao, Y. *et al.* Scn2b Deletion in Mice Results in Ventricular and Atrial Arrhythmias.  
1007 *Circ Arrhythm Electrophysiol* **9**, doi:10.1161/CIRCEP.116.003923 (2016).
- 1008 23 Macías, Á. *et al.* Kir2.1 dysfunction at the sarcolemma and the sarcoplasmic  
1009 reticulum causes arrhythmias in a mouse model of Andersen–Tawil syndrome type  
1010 1. *Nature Cardiovascular Research*, doi:10.1038/s44161-022-00145-2 (2022).
- 1011 24 Takahashi, K. & Yamanaka, S. A decade of transcription factor-mediated  
1012 reprogramming to pluripotency. *Nat Rev Mol Cell Biol* **17**, 183-193,  
1013 doi:10.1038/nrm.2016.8 (2016).
- 1014 25 Lian, X. *et al.* Directed cardiomyocyte differentiation from human pluripotent stem  
1015 cells by modulating Wnt/beta-catenin signaling under fully defined conditions. *Nat*  
1016 *Protoc* **8**, 162-175, doi:10.1038/nprot.2012.150 (2013).
- 1017 26 Lian, X. *et al.* Robust cardiomyocyte differentiation from human pluripotent stem  
1018 cells via temporal modulation of canonical Wnt signaling. *Proc Natl Acad Sci U S A*  
1019 **109**, E1848-1857, doi:10.1073/pnas.1200250109 (2012).
- 1020 27 Herron, T. J., Lee, P. & Jalife, J. Optical imaging of voltage and calcium in cardiac  
1021 cells & tissues. *Circ Res* **110**, 609-623, doi:10.1161/CIRCRESAHA.111.247494  
1022 110/4/609 [pii] (2012).
- 1023 28 Jimenez-Vazquez, E. N. *et al.* SNTA1 Gene Rescues Ion Channel Function in  
1024 Cardiomyocytes Derived from Induced Pluripotent Stem Cells Reprogrammed  
1025 from Muscular Dystrophy Patients with Arrhythmias. *bioRxiv*,  
1026 2022.2001.2025.477696, doi:10.1101/2022.01.25.477696 (2022).

- 1027 29 Hosaka, Y. *et al.* Function, subcellular localization and assembly of a novel  
1028 mutation of KCNJ2 in Andersen's syndrome. *J Mol Cell Cardiol* **35**, 409-415,  
1029 doi:10.1016/s0022-2828(03)00046-4 (2003).
- 1030 30 Andelfinger, G. *et al.* KCNJ2 mutation results in Andersen syndrome with sex-  
1031 specific cardiac and skeletal muscle phenotypes. *Am J Hum Genet* **71**, 663-668,  
1032 doi:10.1086/342360 (2002).
- 1033 31 Plaster, N. M. *et al.* Mutations in Kir2.1 cause the developmental and episodic  
1034 electrical phenotypes of Andersen's syndrome. *Cell* **105**, 511-519,  
1035 doi:10.1016/s0092-8674(01)00342-7 (2001).
- 1036 32 Zhang, L. *et al.* Electrocardiographic features in Andersen-Tawil syndrome patients  
1037 with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2  
1038 genotype. *Circulation* **111**, 2720-2726, doi:10.1161/CIRCULATIONAHA.104.472498  
1039 (2005).
- 1040 33 Leier, C. V., Meacham, J. A. & Schaal, S. F. Prolonged atrial conduction. A major  
1041 predisposing factor for the development of atrial flutter. *Circulation* **57**, 213-216,  
1042 doi:10.1161/01.cir.57.2.213 (1978).
- 1043 34 Caballero, R. *et al.* Flecainide increases Kir2.1 currents by interacting with cysteine  
1044 311, decreasing the polyamine-induced rectification. *Proc Natl Acad Sci U S A* **107**,  
1045 15631-15636, doi:10.1073/pnas.1004021107 (2010).
- 1046 35 Gomez, R. *et al.* Structural basis of drugs that increase cardiac inward rectifier  
1047 Kir2.1 currents. *Cardiovasc Res* **104**, 337-346, doi:10.1093/cvr/cvu203 (2014).
- 1048 36 Hibino, H. *et al.* Inwardly rectifying potassium channels: their structure, function,  
1049 and physiological roles. *Physiol Rev* **90**, 291-366, doi:10.1152/physrev.00021.2009  
1050 (2010).
- 1051 37 Fernandes, C. A. H. *et al.* Cryo-electron microscopy unveils unique structural  
1052 features of the human Kir2.1 channel. *Sci Adv* **8**, eabq8489,  
1053 doi:10.1126/sciadv.abq8489 (2022).
- 1054 38 Donaldson, M. R. *et al.* PIP2 binding residues of Kir2.1 are common targets of  
1055 mutations causing Andersen syndrome. *Neurology* **60**, 1811-1816,  
1056 doi:10.1212/01.wnl.0000072261.14060.47 (2003).
- 1057 39 Handklo-Jamal, R. *et al.* Andersen-Tawil Syndrome Is Associated With Impaired  
1058 PIP(2) Regulation of the Potassium Channel Kir2.1. *Front Pharmacol* **11**, 672,  
1059 doi:10.3389/fphar.2020.00672 (2020).
- 1060 40 Lopes, C. M. *et al.* Alterations in conserved Kir channel-PIP2 interactions underlie  
1061 channelopathies. *Neuron* **34**, 933-944, doi:10.1016/s0896-6273(02)00725-0  
1062 (2002).
- 1063 41 Echt, D. S. *et al.* Mortality and morbidity in patients receiving encainide, flecainide,  
1064 or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med* **324**, 781-788,  
1065 doi:10.1056/NEJM199103213241201 (1991).
- 1066 42 Morganroth, J. Risk factors for the development of proarrhythmic events. *Am J*  
1067 *Cardiol* **59**, 32E-37E, doi:10.1016/0002-9149(87)90199-8 (1987).
- 1068 43 Horowitz, L. N., Greenspan, A. M., Rae, A. P., Kay, H. R. & Spielman, S. R.  
1069 Proarrhythmic responses during electrophysiologic testing. *Am J Cardiol* **59**, 45E-  
1070 48E, doi:10.1016/0002-9149(87)90201-3 (1987).
- 1071 44 Soyka, L. F. Safety of encainide for the treatment of ventricular arrhythmias. *Am J*  
1072 *Cardiol* **58**, 96C-103C, doi:10.1016/0002-9149(86)90111-6 (1986).





- 1073 45 Treatment of life-threatening ventricular tachycardia with encainide hydrochloride  
1074 in patients with left ventricular dysfunction. The Encainide-Ventricular Tachycardia  
1075 Study Group. *Am J Cardiol* **62**, 571-575, doi:10.1016/0002-9149(88)90657-1  
1076 (1988).
- 1077 46 Platia, E. V. *et al.* Flecainide: electrophysiologic and antiarrhythmic properties in  
1078 refractory ventricular tachycardia. *Am J Cardiol* **55**, 956-962, doi:10.1016/0002-  
1079 9149(85)90726-x (1985).
- 1080 47 Fain, E. S., Dorian, P., Davy, J. M., Kates, R. E. & Winkle, R. A. Effects of encainide  
1081 and its metabolites on energy requirements for defibrillation. *Circulation* **73**, 1334-  
1082 1341, doi:10.1161/01.cir.73.6.1334 (1986).
- 1083 48 Reiffel, J. A., Coromilas, J., Zimmerman, J. M. & Spotnitz, H. M. Drug-device  
1084 interactions: clinical considerations. *Pacing Clin Electrophysiol* **8**, 369-373,  
1085 doi:10.1111/j.1540-8159.1985.tb05773.x (1985).
- 1086 49 Winkle, R. A., Mason, J. W., Griffin, J. C. & Ross, D. Malignant ventricular  
1087 tachyarrhythmias associated with the use of encainide. *Am Heart J* **102**, 857-864,  
1088 doi:10.1016/0002-8703(81)90036-3 (1981).
- 1089 50 Morganroth, J. & Horowitz, L. N. Flecaïnide: its proarrhythmic effect and expected  
1090 changes on the surface electrocardiogram. *Am J Cardiol* **53**, 89B-94B,  
1091 doi:10.1016/0002-9149(84)90509-5 (1984).
- 1092 51 S, O. B. *et al.* Increased atrial effectiveness of flecainide conferred by altered  
1093 biophysical properties of sodium channels. *J Mol Cell Cardiol* **166**, 23-35,  
1094 doi:10.1016/j.yjmcc.2022.01.009 (2022).
- 1095 52 Kim, H. S., Pak, H. N., Park, J. S. & Kim, S. S. Flecaïnide-associated bradycardia-  
1096 dependent torsade de pointes: another potential mechanism of proarrhythmia.  
1097 *Pacing Clin Electrophysiol* **36**, e84-86, doi:10.1111/j.1540-8159.2010.02935.x  
1098 (2013).
- 1099 53 Oguayo, K. N., Oyetayo, O. O., Costa, S. M. & Mixon, T. A. An unusual case of  
1100 flecaïnide-induced QT prolongation leading to cardiac arrest. *Pharmacotherapy*  
1101 **34**, e30-33, doi:10.1002/phar.1403 (2014).
- 1102 54 Yang, Y., Lv, T. T., Li, S. Y. & Zhang, P. Sodium channel blockers in the management  
1103 of long QT syndrome types 3 and 2: A system review and meta-analysis. *J*  
1104 *Cardiovasc Electrophysiol* **32**, 3057-3067, doi:10.1111/jce.15223 (2021).
- 1105 55 Arbelo, E. *et al.* 2023 ESC Guidelines for the management of cardiomyopathies.  
1106 *Eur Heart J* **44**, 3503-3626, doi:10.1093/eurheartj/ehad194 (2023).
- 1107 56 Kannankeril, P. J., Roden, D. M. & Fish, F. A. Suppression of bidirectional  
1108 ventricular tachycardia and unmasking of prolonged QT interval with verapamil in  
1109 Andersen's syndrome. *J Cardiovasc Electrophysiol* **15**, 119, doi:10.1046/j.1540-  
1110 8167.2004.03369.x (2004).
- 1111 57 Miyamoto, K. *et al.* Efficacy and safety of flecainide for ventricular arrhythmias in  
1112 patients with Andersen-Tawil syndrome with KCNJ2 mutations. *Heart Rhythm* **12**,  
1113 596-603, doi:10.1016/j.hrthm.2014.12.009 (2015).
- 1114 58 Pellizzon, O. A., Kalaizich, L., Ptacek, L. J., Tristani-Firouzi, M. & Gonzalez, M. D.  
1115 Flecaïnide suppresses bidirectional ventricular tachycardia and reverses  
1116 tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. *J Cardiovasc*  
1117 *Electrophysiol* **19**, 95-97, doi:10.1111/j.1540-8167.2007.00910.x (2008).
- 1118 59 Sansone, V. & Tawil, R. Management and treatment of Andersen-Tawil syndrome  
1119 (ATS). *Neurotherapeutics* **4**, 233-237, doi:10.1016/j.nurt.2007.01.005 (2007).

- 1120 60 Bokenkamp, R., Wilde, A. A., Schalij, M. J. & Blom, N. A. Flecainide for recurrent  
1121 malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.  
1122 *Heart Rhythm* **4**, 508-511, doi:10.1016/j.hrthm.2006.12.031 (2007).
- 1123 61 Haruna, Y. *et al.* Genotype-phenotype correlations of KCNJ2 mutations in Japanese  
1124 patients with Andersen-Tawil syndrome. *Hum Mutat* **28**, 208,  
1125 doi:10.1002/humu.9483 (2007).
- 1126 62 Fox, D. J. *et al.* Reduction of complex ventricular ectopy and improvement in  
1127 exercise capacity with flecainide therapy in Andersen-Tawil syndrome. *Europace*  
1128 **10**, 1006-1008, doi:10.1093/europace/eun180 (2008).
- 1129 63 Barajas-Martinez, H. *et al.* Biophysical and molecular characterization of a novel  
1130 de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and  
1131 catecholaminergic polymorphic ventricular tachycardia mimicry. *Circ Cardiovasc*  
1132 *Genet* **4**, 51-57, doi:10.1161/CIRCGENETICS.110.957696 (2011).
- 1133 64 Janson, C. M., Poelzing, S. & Shah, M. J. Combined inhibition of Na(+) and Ca(2+)  
1134 channels: a novel paradigm for the treatment of incessant ventricular arrhythmias  
1135 in Andersen-Tawil syndrome. *Heart Rhythm* **11**, 318-320,  
1136 doi:10.1016/j.hrthm.2013.11.003 (2014).
- 1137 65 Bienias, P., Kostera-Pruszczyk, A., Miszczak-Knecht, M., Ciurzynski, M. & Pruszczyk,  
1138 P. Propafenone is not effective for severe ventricular arrhythmias in Andersen-  
1139 Tawil syndrome. *Arch Med Sci* **14**, 248-250, doi:10.5114/aoms.2016.61010 (2018).
- 1140 66 Van Ert, H. A. *et al.* Flecainide treats a novel KCNJ2 mutation associated with  
1141 Andersen-Tawil syndrome. *HeartRhythm Case Rep* **3**, 151-154,  
1142 doi:10.1016/j.hrcr.2016.11.009 (2017).
- 1143 67 Fernandez, M. *et al.* Response to flecainide test in Andersen-Tawil syndrome with  
1144 incessant ventricular tachycardia. *Pacing Clin Electrophysiol* **41**, 429-432,  
1145 doi:10.1111/pace.13204 (2018).
- 1146 68 Rujirachun, P., Junyavoraluk, A., Pithukpakorn, M., Suktitipat, B. & Winijkul, A.  
1147 Successful treatment of arrhythmia with beta-blocker and flecainide combination  
1148 in pregnant patients with Andersen-Tawil syndrome: A case report and literature  
1149 review. *Ann Noninvasive Electrocardiol* **26**, e12798, doi:10.1111/anec.12798  
1150 (2021).
- 1151 69 Ergul, Y., Ozgur, S., Onan, S. H. & Tuzcu, V. Can flecainide totally eliminate  
1152 bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil  
1153 syndrome? *Turk Kardiyol Dern Ars* **46**, 718-722,  
1154 doi:10.5543/tkda.2018.10.5543/tkda.2017.77856 (2018).
- 1155 70 Nguyen, D. & Ferns, S. J. Asymptomatic ventricular tachycardia: diagnostic pitfalls  
1156 of Andersen-Tawil syndrome-a case report. *Eur Heart J Case Rep* **2**, yty083,  
1157 doi:10.1093/ehjcr/yty083 (2018).
- 1158 71 Sato, A., Takano, T., Chinushi, M. & Minamino, T. Usefulness of the intravenous  
1159 flecainide challenge test before oral flecainide treatment in a patient with  
1160 Andersen-Tawil syndrome. *BMJ Case Rep* **12**, doi:10.1136/bcr-2019-229628  
1161 (2019).
- 1162 72 Maffe, S. *et al.* Therapeutic management of ventricular arrhythmias in Andersen-  
1163 Tawil syndrome. *J Electrocardiol* **58**, 37-42, doi:10.1016/j.jelectrocard.2019.10.009  
1164 (2020).

- 1165 73 Hayashi, H., Kawaguchi, T. & Horie, M. Effect of flecainide on T-wave alternans in  
1166 Andersen-Tawil syndrome. *Ann Noninvasive Electrocardiol* **19**, 383-386,  
1167 doi:10.1111/anec.12144 (2014).
- 1168 74 Junker, J. *et al.* Amiodarone and acetazolamide for the treatment of genetically  
1169 confirmed severe Andersen syndrome. *Neurology* **59**, 466,  
1170 doi:10.1212/wnl.59.3.466 (2002).
- 1171 75 Erdogan, O. *et al.* Oral verapamil effectively suppressed complex ventricular  
1172 arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome. *J*  
1173 *Electrocardiol* **41**, 325-328, doi:10.1016/j.jelectrocard.2008.02.023 (2008).
- 1174 76 Weir, R. A., Petrie, C. J., Murday, V. & Findlay, I. N. Andersen-Tawil syndrome. *Int J*  
1175 *Cardiol* **148**, e13-15, doi:10.1016/j.ijcard.2009.01.057 (2011).
- 1176 77 Delannoy, E. *et al.* Cardiac characteristics and long-term outcome in Andersen-  
1177 Tawil syndrome patients related to KCNJ2 mutation. *Europace* **15**, 1805-1811,  
1178 doi:10.1093/europace/eut160 (2013).
- 1179 78 Keegan, R., Onetto, L., Gregoriotti, F., Urruti, R. & Di Biase, L. Catheter ablation of  
1180 frequent monomorphic ventricular arrhythmias in Andersen-Tawil syndrome: case  
1181 report and focused literature review. *J Interv Card Electrophysiol* **66**, 729-736,  
1182 doi:10.1007/s10840-021-01077-w (2023).
- 1183 79 Abriel, H., Rougier, J. S. & Jalife, J. Ion channel macromolecular complexes in  
1184 cardiomyocytes: roles in sudden cardiac death. *Circ Res* **116**, 1971-1988,  
1185 doi:10.1161/CIRCRESAHA.116.305017 (2015).
- 1186 80 Meadows, L. S. & Isom, L. L. Sodium channels as macromolecular complexes:  
1187 implications for inherited arrhythmia syndromes. *Cardiovasc Res* **67**, 448-458,  
1188 doi:10.1016/j.cardiores.2005.04.003 (2005).
- 1189 81 Willis, B. C., Ponce-Balbuena, D. & Jalife, J. Protein assemblies of sodium and  
1190 inward rectifier potassium channels control cardiac excitability and  
1191 arrhythmogenesis. *Am J Physiol Heart Circ Physiol* **308**, H1463-1473,  
1192 doi:10.1152/ajpheart.00176.2015 (2015).
- 1193 82 Singer, D. H., Lazzara, R. & Hoffman, B. F. Interrelationship between automaticity  
1194 and conduction in Purkinje fibers. *Circ Res* **21**, 537-558,  
1195 doi:10.1161/01.res.21.4.537 (1967).
- 1196 83 DeMarco, K. R. & Clancy, C. E. Cardiac Na Channels: Structure to Function. *Curr*  
1197 *Top Membr* **78**, 287-311, doi:10.1016/bs.ctm.2016.05.001 (2016).
- 1198 84 Bagal, S. K., Marron, B. E., Owen, R. M., Storer, R. I. & Swain, N. A. Voltage gated  
1199 sodium channels as drug discovery targets. *Channels (Austin)* **9**, 360-366,  
1200 doi:10.1080/19336950.2015.1079674 (2015).
- 1201 85 Noujaim, S. F. *et al.* Up-regulation of the inward rectifier K<sup>+</sup> current (I<sub>K1</sub>) in the  
1202 mouse heart accelerates and stabilizes rotors. *J Physiol* **578**, 315-326,  
1203 doi:jphysiol.2006.121475 [pii]  
1204 10.1113/jphysiol.2006.121475 (2007).
- 1205 86 Scheinman, M. M. Role of the His-Purkinje system in the genesis of cardiac  
1206 arrhythmia. *Heart Rhythm* **6**, 1050-1058, doi:10.1016/j.hrthm.2009.03.011 (2009).
- 1207 87 Riera, A. R. *et al.* Relationship among amiodarone, new class III antiarrhythmics,  
1208 miscellaneous agents and acquired long QT syndrome. *Cardiol J* **15**, 209-219  
1209 (2008).


- 1210 88 Follmer, C. H. & Colatsky, T. J. Block of delayed rectifier potassium current, IK, by  
1211 flecainide and E-4031 in cat ventricular myocytes. *Circulation* **82**, 289-293,  
1212 doi:10.1161/01.cir.82.1.289 (1990).
- 1213 89 Wang, D. W., Kiyosue, T., Sato, T. & Arita, M. Comparison of the effects of class I  
1214 anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed  
1215 rectifier K<sup>+</sup> current of guinea-pig ventricular myocytes. *J Mol Cell Cardiol* **28**, 893-  
1216 903, doi:10.1006/jmcc.1996.0084 (1996).
- 1217 90 Paul, A. A., Witchel, H. J. & Hancox, J. C. Inhibition of the current of heterologously  
1218 expressed HERG potassium channels by flecainide and comparison with quinidine,  
1219 propafenone and lignocaine. *Br J Pharmacol* **136**, 717-729,  
1220 doi:10.1038/sj.bjp.0704784 (2002).
- 1221 91 Melgari, D., Zhang, Y., El Harchi, A., Dempsey, C. E. & Hancox, J. C. Molecular basis  
1222 of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. *J*  
1223 *Mol Cell Cardiol* **86**, 42-53, doi:10.1016/j.yjmcc.2015.06.021 (2015).
- 1224 92 Hoffmann, A., Wenk, M. & Follath, F. Exercise-induced ventricular tachycardia as a  
1225 manifestation of flecainide toxicity. *Int J Cardiol* **11**, 353-355, doi:10.1016/0167-  
1226 5273(86)90040-9 (1986).
- 1227 93 Anastasiou-Nana, M. I. *et al.* Occurrence of exercise-induced and spontaneous  
1228 wide complex tachycardia during therapy with flecainide for complex ventricular  
1229 arrhythmias: a probable proarrhythmic effect. *Am Heart J* **113**, 1071-1077,  
1230 doi:10.1016/0002-8703(87)90914-8 (1987).
- 1231 94 Ranger, S., Talajic, M., Lemery, R., Roy, D. & Nattel, S. Amplification of flecainide-  
1232 induced ventricular conduction slowing by exercise. A potentially significant  
1233 clinical consequence of use-dependent sodium channel blockade. *Circulation* **79**,  
1234 1000-1006, doi:10.1161/01.cir.79.5.1000 (1989).
- 1235 95 Watanabe, H. *et al.* Effects of flecainide on exercise-induced ventricular  
1236 arrhythmias and recurrences in genotype-negative patients with  
1237 catecholaminergic polymorphic ventricular tachycardia. *Heart Rhythm* **10**, 542-  
1238 547, doi:10.1016/j.hrthm.2012.12.035 (2013).
- 1239 96 Radicke, S. *et al.* Effects of MiRP1 and DPP6 beta-subunits on the blockade  
1240 induced by flecainide of Kv4.3/KChIP2 channels. *Br J Pharmacol* **154**, 774-786,  
1241 doi:10.1038/bjp.2008.134 (2008).
- 1242 97 Krishnan, S. C. & Antzelevitch, C. Flecainide-induced arrhythmia in canine  
1243 ventricular epicardium. Phase 2 reentry? *Circulation* **87**, 562-572,  
1244 doi:10.1161/01.cir.87.2.562 (1993).
- 1245 98 Ikeda, N., Singh, B. N., Davis, L. D. & Hauswirth, O. Effects of flecainide on the  
1246 electrophysiologic properties of isolated canine and rabbit myocardial fibers. *J Am*  
1247 *Coll Cardiol* **5**, 303-310, doi:10.1016/s0735-1097(85)80051-6 (1985).
- 1248 99 Osadchii, O. E. Flecainide-induced proarrhythmia is attributed to abnormal  
1249 changes in repolarization and refractoriness in perfused guinea-pig heart. *J*  
1250 *Cardiovasc Pharmacol* **60**, 456-466, doi:10.1097/FJC.0b013e31826b86cf (2012).
- 1251 100 Osadchii, O. E. Effects of Na<sup>+</sup> channel blockers on extrasystolic stimulation-evoked  
1252 changes in ventricular conduction and repolarization. *J Cardiovasc Pharmacol* **63**,  
1253 240-251, doi:10.1097/FJC.0000000000000041 (2014).
- 1254 101 Hilliard, F. A. *et al.* Flecainide inhibits arrhythmogenic Ca<sup>2+</sup> waves by open state  
1255 block of ryanodine receptor Ca<sup>2+</sup> release channels and reduction of Ca<sup>2+</sup> spark  
1256 mass. *J Mol Cell Cardiol* **48**, 293-301, doi:10.1016/j.yjmcc.2009.10.005 (2010).

- 1257 102 Al-Khatib, S. M. *et al.* 2017 AHA/ACC/HRS Guideline for Management of Patients  
1258 With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A  
1259 Report of the American College of Cardiology/American Heart Association Task  
1260 Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*  
1261 **138**, e272-e391, doi:10.1161/CIR.0000000000000549 (2018).
- 1262 103 Bannister, M. L., MacLeod, K. T. & George, C. H. Moving in the right direction:  
1263 elucidating the mechanisms of interaction between flecainide and the cardiac  
1264 ryanodine receptor. *Br J Pharmacol* **179**, 2558-2563, doi:10.1111/bph.15718  
1265 (2022).  
1266

**A****Kir2.1 c.365 A>T p.Cys122Tyr (C122Y);****B****Kir2.1 c.644 G>A, Gly215Asp (G215D)**


Nadolol + Flecainide

(II.1)

**C****Kir2.1 c.199 C>T, Arg67Trp (R67W)**


Nadolol + Propafenone

(II.1)



A

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.10.24318629>; this version posted December 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.





B


**Input**

| Response to class-Ic AADs                   | Nº of patients       | References   |
|---|----------------------|--|
| Successful treatment                        | (12)                 |  |
| Complete VAs suppression                    | <b>9 (16.9%)</b>     | Bökenkamp; Haruna; Pellizón; Barajas; Van Ert*                             |
| >90% VAs suppression                        | <b>3 (5.6%)*,*,†</b> | Ergül; Fernandez; Nguyen <sup>#</sup> ; Maffè <sup>‡</sup> ; Rujirachun    |
| Partial recovery                            | (33)                 |  |
| >90% VAs suppression                        | <b>3 (5.6%)*,*,†</b> | Fox; Hayashi; Janson; Miyamoto; Bienias; Van Ert*;                         |
| <90% VAs reduction                          | <b>28 (52.8%)</b>    | Nguyen <sup>#</sup> ; Sato; Mazzanti; Maffè <sup>‡</sup> ; Case 1 daughter |
| Ineffective treatment                       |                      |  |
| Ineffective                                 | <b>13 (24.5%)</b>    | Junker; Erdogan; Weir; Delannoy; Keegan; Cruz; Case 1; Case 2              |
| <b>Overall number of unique probands 53</b> |                      |  |
| Non-fatal cardiac arrest (ICD shock)        | (7) <b>(13.2%)</b>   |  |
| Reported as >90% VAs suppression            | <b>1 (1.9%)</b>      | Maffè  |
| Reported as partial recovery                | <b>3 (5.7%)</b>      | Bökenkamp; Mazzanti  |
| Reported as ineffective                     | <b>3 (5.7%)</b>      | Junker; Delannoy; Cruz   |


\*,\*,† same patient; VAs: Ventricular arrhythmias


**A****Flecainide****B****Propafenone**






**Cruz et al. Figure 4**






**Cruz et al. Figure 6**



**Cruz et al. Figure 7**



**Cruz et al. Figure 8**

**Tabla 1. Response to class-Ic antiarrhythmic drugs in the treatment of Andersen-Tawil syndrome type 1**

| Sex           | KCNJ2 mutation                          | Cardiac phenotype   | Tested therapy  | Reported Class Ic treatment response   | References                     |
|---------------|---|---|---|--|--------------------------------|
| F             | R218W                                   | Polymorphic PVCs, VF  | Sotalol, flecainide, propafenone<br>Amiodarone + acetazolamide  | Aborted sudden cardiac death under flecainide.<br>Only amiodarone was effective in treating the arrhythmias.   | Junker J et al. (2002)         |
| F             | R218W                                   | PVT, TdP tachycardia, VF,<br>prominent U waves  | i.v. Flecainide 0.5mg/Kg<br>Oral verapamil + flecainide 4 mg/kg/day<br>ICD  | One appropriate ICD shock for TdP tachycardia after 3 years of flecainide treatment.<br>Still shows frequent polymorphic PVCs, but no VT.  | Bökenkamp et al. (2007)        |
| M             | R218W                                   | TdP tachycardia   | Oral flecainide 4 mg/kg/day   | Asymptomatic during 5 years follow-up.   |                                |
| F             | NR                                      | PVCs, bigeminy, Couplets<br>BiVT, VT  | Oral flecainide   | Flecainide suppressed cardiac arrhythmias.   | Haruna et al. (2007)           |
| F             | R67W                                    | BiVT  | Oral flecainide 200 mg/day for 3year<br>then switched to 300mg/day  | Two BiVT recurrences and tachycardia-induced cardiomyopathy (LVEF:25%).<br>Improvement (LVEF:55%) after increasing flecainide doses.   | Pellizzón et al. (2008)        |
| F             | NR                                      | Polymorphic PVCs, BiVT,<br>bigeminy, NSVT, U-waves  | i.v. propafenone<br>verapamil   | Propafenone was not effective in treating the arrhythmias.<br>Verapamil revealed absence of BiVT and NSVT with frequent bigeminy episodes  | Erdogan O et al. (2008)        |
| M             | V302M                                   | BiVT, NSPVT, PVCs<br>24h Holter: 15671 total PVC;<br>1912 couplets; 358 runs of NSVT              | Bisoprolol 5mg/day switched<br>to oral flecainide 200 mg/day  | Bisoprolol demonstrated no significant arrhythmia reduction.<br>Flecainide reduced PVCs to 268; 11 couplets and no runs of VT in 24h monitoring.   | Fox et al. (2008)              |
| F             | R206P                                   | Ventricular extrasystole, BiVT, NSPVT   | Nadolol switched<br>to flecainide 2 mg/kg/day   | Flecainide suppressed BiVT. Sporadic ventricular extrasystoles.  | Barajas-Martinez et al. (2011) |
| F             | R218W                                   | Palpitation, extrasystoles  | Propranolol, amiodarone, flecainide<br>atenolol   | Only atenolol improved her palpitations.   | Weir et al. (2014)             |
| serie<br>N=6  | NR                                      | Polymorphic PVCs, NSVT, VT  | $\beta$ -blocker + flecainide   | One of them experienced a non-fatal cardiac arrest related<br>to PVT with NSVT under treatment.  | Delannoy et al. (2014)         |
| M             | R67Q                                    | Couplet, triplet PVCs, NSVT<br>24h Holter: 19389 total PVC;<br>2964 couplets; 91 triplets; 4 NSVT | Oral flecainide 100 mg/day<br>+ atenolol 50mg/day   | Couplet, triplet PVCs, NSVT<br>24h Holter: 10854 total PVC; 245 couplets; 9 triplets; 1 quadrat PVCs.  | Hayashi et al. (2014)          |
| M             | R218W                                   | High-burden ventricular ectopy: 40846/day;<br>467 VT/day  | Nadolol, mexiletine, flecainide<br>amiodarone and verapamil   | Neither antiarrhythmic monotherapy nor verapamil + low doses flecainide<br>resulted in significant improvement. Verapamil + flecainide 4 mg/kg/day each<br>resulted in decreased ectopy: 5390/day.                           | Janson et al. (2014)           |
| serie<br>N=10 | R67Q/W, R218Q/W<br>G300V, G301T, 76insT | Couplet PVCs, BiVT, NSVT<br>VA: 38407/day   | Oral flecainide 100-200 mg/day  | Significantly reduced the total number of VA: 11196/day.   | Miyamoto K et al. (2015)       |
| F             | G146R                                   | bigeminy, trigeminy and BiVT<br>VA: ~ 55000/day   | Propafenone 450 mg/day + metoprolol 50/mg/day<br>switched to flecainide 200 mg/day  | Propafenone increased Va slightly (400-800 episodes BiVT/day).<br>Only flecainide reduced VA to ~7500/day and 5-20 short BiVT.   | Bienias P et al. (2016)        |
| F             | R218L                                   | Polymorphic PVC, bigeminy PVC<br>PVT, BiVT  | Flecainide 200 mg/day<br>+ atenolol 25 mg/day   | After two ablation, proband showed transient improvement.<br>Flecainide 100 mg/day was titrated up to 200 mg/day to suppress BiVT and PMVT,<br>with PVCs burden decreased to <1%. She later experienced periodic paralysis.  | Van Ert et al. (2016)          |
| F             | V200M                                   | Polymorphic PVC, BiVT, NSVT<br>PQTc, U waves  | Propranolol 4mg/Kg/day+<br>flecainide 100 mg/m <sup>2</sup> /day<br>Bisoprolol 5mg/day<br>Flecainide 200 mg/day<br>Acetazolamide 250 mg/day | $\beta$ -blocker alone was not sufficient to control PVCs. Combined with flecainide<br>almost all PVCs disappeared. QTc interval shortened but U waves persisted.  | Ergül Y et al. (2018)          |
| F             | T305I                                   | Palpitations, high burden PVCs,<br>bigeminy PVCs  | Sotalol 150mg/m <sup>2</sup> /day<br>Flecainide 200 mg/day<br>Acetazolamide 250 mg/day  | Bisoprolol did not suppress PVCs. Bisoprolol + flecainide + acetazolamide<br>suppressed palpitation and reduced PVC burden.  | Fernández et al. (2018)        |
| F             | D71N                                    | runs of NSBiVT, PQTc,<br>VE 45%   | Propafenone 300mg/m <sup>2</sup> /day + metoprolol 3mg/kg/day<br>Flecainide 4mg/kg/day + nadolol 0.75mg/kg/day                              | Sotalol had no effect. During first 9 months propafenone combined with<br>metoprolol reduced VE to 3-6% and then progressive increased to 40%.<br>Switched to flecainide + nadolol reduced VE to <5% in 10-month follow-up.  | Nguyen D et al. (2018)         |
| F             | R228insKSHLVEAHVR                       | PVCs, NSVT<br>24h Holter: 50133 PVCs  | Disopyramide, mexiletine, pilsicainide and verapamil<br>Atenolol (25mg)<br>i.v. flecainide 30mg / oral flecainide 100mg                     | Disopyramide, mexiletine, pilsicainide, verapamil and $\beta$ -blocker failed to<br>suppress VAs. i.v. flecainide suppressed VAs completely; oral flecainide<br>100mg/day reduced PVC to 13363 PVCs/day in follow-up Holter. | Sato A et al. (2019)           |

**Tabla 1. Response to class-Ic antiarrhythmic drugs in the treatment of Andersen-Tawil syndrome type 1**

| Age/Sex       | KCNJ2 mutation | Cardiac phenotype   | Tested therapy  | Reported Class Ic treatment response   | References                 |
|---------------|----------------|---|---|--|----------------------------|
| serie<br>N=12 | NR             | BiVT, bigeminy PVCs, PQTC + U-waves<br>Holter VA: 15940 ± 17106                                   | β-blocker + class Ic antiarrhythmics<br>propafenone/flecainide:<br>6.5±3.1 and 2.5±1.3 mg/kg/day  | Flecainide and propafenone might be useful to reduce the arrhythmic burden.<br>They were not useful in preventing life-threatening arrhythmias.<br>Holter VA:3459±8849; two experienced cardiac arrest while on treatment. | Mazzanti et al. (2020)     |
| F             | T192I          | Polymorphic PVC, bigeminy<br>24h Holter: 17000 VE, 900 couplets,<br>80 NSPVT; PQTC                | Oral flecainide (200mg/day)<br>ICD after suffering non-fatal cardiac arrest   | Follow-up at 2 years showed reduction in VA to 18 isolated VE per day,<br>Prolonged QTc and U-waves.<br>Non-fatal cardiac arrest with VF.  | Maffè et al. (2020)        |
| F             | P186R          | PVT, NSPVT, Polymorphic PVCs  | Flecainide 100 mg/day<br>Metoprolol 100 mg/day  | Suppressed NSPVT at 5 months of follow-up.<br><br>Ventricular ectopy less frequent. No VTs.  | Rujirachun P et al. (2020) |
| F             | P186R          | IBiVT, bigeminy PVCs  |   | Follow-up at 4 months showed U-waves and occasional ventricular ectopy.  |                            |
| F             | M307V          | Polymorphic PVCs,<br>PQTC, U-waves  | Atenolol, Propranolol, Bisoprolol<br>alone or combined with Flecainide 2 mg/kg/day.<br>CA + flecainide and propranolol (2-2,5mg/kg/day) | β-blocker alone failed to reduce PVC; β-blocker combined with flecainide<br>resulted in: PVCs >14-34%, NS BiVT.<br>After CA: high burden PVC (55%).  | Keegan et al. (2023)       |
| F             | C122Y          | Polymorphic PVCs, NSVT, trigeminy<br>PQTC, U-waves  | Mexiletine, propafenone, lidocaine<br>Nadolol (120mg/day) + spironolactone (25 mg/day)  | Polymorphic ventricular extrasystoles refractory to antiarrhythmic drugs<br>(mexiletine, lidocaine, propafenone) with three appropriate ICD  | Cruz et al. (2023)         |
| F             | G215D          | dyspnea, fatigue, palpitations<br>and dizziness with persistent<br>ventricular bigeminy and NSPVT | Nadolol (20 mg/day) + flecainide (100 mg/day)<br>switched to propafenone (225 mg/day) and<br>mexiletine (7,7 mg/kg/day)                 | Increase in ventricular ectopies under Nadolol + Flecainide (18%),<br>Nadolol + propafenone (11,2%) and Nadolol + mexiletine (13%).<br>Currently under Nadolol (up to 13% of VE).  | Case 1                     |
| F             | G215D          | Asymptomatic, BiVT,<br>persistent ventricular bigeminy  | Nadolol (20 mg/day) + flecainide (100 mg/day)<br>switched to propafenone (375 mg/day) + ICD   | 35% VA under flecainide; 10% VA under propafenone.<br>Currently remains clinically stable, but VAs do not disappear completely.  | Case 1 - daughter          |
| M             | R67W           | VE, NSVT,<br>Palpitations, PQTC, U-waves  | Nadolol (120mg/day) + Acetazolamide (250 mg/day)<br>switched to flecainide (200mg/day).<br>Reverted to Nadolol (80 mg/day)              | Flecainide induced an asymptomatic 8-sec cardiac pause and<br>extreme nodal bradycardia (minimum of 28 bpm). VE persist.   | Case 2                     |

Abbreviations: BiVT, bidirectional ventricular tachycardia; CA, catheter ablation; IBiVT, incessant bidirectional ventricular tachycardia; i.v., intravenous; NR, not reported; NSPVT, nonsustained polymorphic ventricular tachycardia; PQTC, prolonged QTc; PVT, polymorphic ventricular tachycardia; PVCs, premature ventricular contractions; TdP, torsade de pointes; VA: ventricular arrhythmia; VE: ventricular ectopy VF, ventricular fibrillation; VT, ventricular tachycardia.